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ABSTRACT
Patient- reported outcomes (PROs) are used in clinical 
trials to provide valuable evidence on the impact of 
disease and treatment on patients’ symptoms, function 
and quality of life. High- quality PRO data from trials can 
inform shared decision- making, regulatory and economic 
analyses and health policy. Recent evidence suggests the 
PRO content of past trial protocols was often incomplete 
or unclear, leading to research waste. To address this 
issue, international, consensus- based, PRO- specific 
guidelines were developed: the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT)- PRO 
Extension. The SPIRIT- PRO Extension is a 16- item checklist 
which aims to improve the content and quality of aspects 
of clinical trial protocols relating to PRO data collection 
to minimise research waste, and ultimately better inform 
patient- centred care. This SPIRIT- PRO explanation and 
elaboration (E&E) paper provides information to promote 
understanding and facilitate uptake of the recommended 
checklist items, including a comprehensive protocol 
template. For each SPIRIT- PRO item, we provide a 
detailed description, one or more examples from existing 
trial protocols and supporting empirical evidence of 
the item’s importance. We recommend this paper and 
protocol template be used alongside the SPIRIT 2013 and 
SPIRIT- PRO Extension paper to optimise the transparent 
development and review of trial protocols with PROs.
BACKGROUND
Clinical trial protocols are essential docu-
ments intended to include the study ratio-
nale, intervention, trial design methods, 
study processes, outcomes, sample size, data 
collection procedures, proposed analyses and 
ethical considerations. Provision of sufficient 
detail is necessary to enable the research 
team to conduct a high- quality, reproducible 
study. It also facilities external appraisal of 
Strengths and limitations of this study
 ► The Standard Protocol Items: Recommendations 
for Interventional Trials (SPIRIT)- patient- reported 
outcome (PRO) Extension aims to improve the com-
pleteness and transparency of trial protocols where 
PROs are a primary or key secondary outcomes and 
was developed following Enhancing Quality and 
Transparency of Health Research Network Guidance.
 ► This explanation and elaboration paper provides 
information to promote understanding and facilitate 
uptake of the recommended PRO protocol SPIRIT- 
PRO checklist items for clinical trials.
 ► A comprehensive protocol template and selected 
examples from existing trial protocols are provided 
to facilitate implementation.
 ► The protocol template and explanation and elabo-
ration paper were developed with multistakeholder 
international input including: trialists, PRO method-
ologists, psychometricians, patient partners, indus-
try representatives, journal editors, regulators and 
ethicists.
 ► Although the guidance is limited in focus to clinical 
trials, many of the SPIRIT- PRO items may also pro-
vide useful prompts about PRO content for cohort 
studies and other non- randomised designs.
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the scientific, methodological and ethical rigour of the 
trial by relevant stakeholders.1 2 Although trial protocols 
serve as the foundation for study planning, conduct, 
reporting and appraisal, they vary greatly in content and 
quality.1 2 Appraisals of the patient- reported outcome 
(PRO) content of over 350 past trial protocols revealed 
that many protocols lack specific information needed 
for high- quality PRO data collection and evidence gener-
ation (online supplemental 1).3–5 As a result, research 
personnel and potential research participants may not 
appreciate the purpose of PRO data collection,6 and the 
need for standardised PRO assessment methods. This 
may result in high levels of missing data and poor quality 
or non- reporting of PRO trial results, which may hinder 
the potential for PRO evidence to be used in regulatory 
decision- making, health policy and clinical care.6–8 For 
example, a recent review of cancer portfolio trials illus-
trates this point; recommended PRO protocol content 
was frequently not addressed and PRO data from 61 trials, 
including 49 568 participants, was unpublished.9 Another 
trial also cited poor PRO completion rates as the reason 
for not publishing PRO data—and the corresponding 
trial protocol included only sparse guidance related to 
the PRO study.7
In 2013, core protocol guidelines applicable to all 
types of trials was published based on expert consensus 
and research evidence, in the form of the Standard 
Protocol Items: Recommendations for Interventional 
Trials (SPIRIT) 2013 statement. Its corresponding 
SPIRIT 2013 explanation and elaboration (E&E) paper 
provides important information to promote full under-
standing of, and assist protocol writers to implement, the 
33 checklist recommendations.1 2 However, SPIRIT 2013 
does not provide specific recommendations about PRO 
endpoints. PROs can provide valuable information on 
the risks, benefits and tolerability of an intervention. PRO 
data are intrinsically subjective, requiring completion by 
patient- participants within a specific time frame and, as 
a result, present a range of scientific and logistical chal-
lenges for researchers which should be addressed in the 
trial protocol.6 10–12
To address this issue, international stakeholders 
worked to develop the SPIRIT- PRO Extension, with the 
aim of improving PRO content of trial protocols and 
supporting documents, for use in conjunction with 
SPIRIT 2013 Guidelines and E&E papers.1 2 The SPIR-
IT- PRO Extension was published in 2018 and comprises 
11 extensions (new, PRO- specific items) and 5 elabora-
tions (an elaboration of an existing SPIRIT 2013 item as 
applied to clinical trials assessing PROs) recommended 
for inclusion in clinical trial protocols that have PROs 
as primary or key secondary outcomes (table 1).10 The 
SPIRIT- PRO Extension paper reports the 16 items and 
describes the methods used to develop the checklist, but 
does not provide detailed implementation instructions or 
examples. This SPIRIT- PRO E&E paper aims to promote 
understanding of the guidelines, provide real examples 
of SPIRIT- PRO items being addressed from a range of 
different trials and facilitate uptake of the recommended 
checklist items. A table of contents detailing where to find 
an example and explanation of each item is provided in 
table 2. In addition, we describe the development of a 
new PRO protocol template (online supplemental file 2) 
for use in protocol development. Additional information 
and resources regarding the SPIRIT Initiative are avail-
able on the SPIRIT website ( www. spirit- statement. org).
The development of the SPIRIT- PRO Extension 
followed the Enhancing Quality and Transparency of 
Health Research Network’s methodological framework 
for guideline development,13 and has been published 
elsewhere.10 Briefly, these methods included:
1. a systematic review of existing PRO- specific protocol 
guidelines to generate the list of potential PRO- specific 
protocol items;14
2. refinements to the list and removal of duplicate items 
by the International Society for Quality of Life Re-
search (ISOQOL) Protocol Checklist Taskforce;
3. an international stakeholder survey of trial research 
personnel, PRO methodologists, health economists, 
psychometricians, patient advocates, funders, industry 
representatives, journal editors, policy makers, ethi-
cists and researchers responsible for evidence synthe-
sis (distributed by 38 international partner organisa-
tions);
4. an international Delphi exercise;
5. a consensus meeting in May 2017 to finalise the guide-
lines and implementation strategy.
International stakeholders provided feedback on the final 
wording of the SPIRIT- PRO Extension during a final 3- week 
consultation period. Following minor edits, the guidelines 
were finalised and agreed by the SPIRIT- PRO Group.10
DEVELOPMENT OF THE PRO PROTOCOL TEMPLATE
A PRO protocol template was developed to support imple-
mentation of the SPIRIT- PRO guidance (ethical approval 
ERN_19–0939). The draft template was reviewed by 
members of the project team and broader SPIRIT- PRO 
Group, including patient partners. In addition, an inter-
national advisory group (IAG), comprising global PRO 
leads from major pharmaceutical companies, regulators 
and academics, was convened to review and provide addi-
tional feedback on the template. Teleconference meet-
ings were held with members of the SPIRIT- PRO Group 
and the IAG to discuss the feedback received. Based on 
the feedback, the template was revised and sent to all for 
final comments. After a final consultation period, the 
PRO protocol template was revised and finalised.
PATIENT AND PUBLIC INVOLVEMENT
Patient partners were involved in the design, conduct, 
reporting and dissemination plans of our research, 
including development of the SPIRIT- PRO Extension, the 
E&E paper, protocol template, tools to support implemen-
tation by patient partners and are included as coauthors.15
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Table 2 Table of contents and resources
SPIRIT- PRO 
item no. Item title SPIRIT- PRO extension or elaboration item description
Page number of 
example/explanation
5a SPIRIT5a- PRO Elaboration Specify the individual(s) responsible for the PRO content of the trial protocol. 11–12
6a SPIRIT6a- PRO Extension Describe the PRO- specific research question and rationale for PRO 
assessment and summarise PRO findings in relevant studies.
12
7 SPIRIT7- PRO Extension State- specific PRO objectives or hypotheses (including relevant PRO 
concepts/domains).
12–14
10 SPIRIT10- PRO Extension Specify any PRO- specific eligibility criteria (eg, language/reading 
requirements or prerandomisation completion of PRO). If PROs will not be 
collected from the entire study sample, provide a rationale and describe the 
method for obtaining the PRO subsample.
14
12 SPIRIT12- PRO Extension Specify the PRO concepts/domains used to evaluate the intervention (eg, 
overall health- related quality of life, specific domain, specific symptom) and, 
for each one, the analysis metric (eg, change from baseline, final value, time 
to event) and the principal timepoint or period of interest.
14–16
13 SPIRIT13- PRO Extension Include a schedule of PRO assessments, providing a rationale for the 
timepoints and justifying if the initial assessment is not prerandomisation. 
Specify time- windows, whether PRO collection is prior to clinical 
assessments, and, if using multiple questionnaires, whether order of 
administration will be standardised.
16–17
14 SPIRIT14- PRO Elaboration When a PRO is the primary endpoint, state the required sample size (and 
how it was determined) and recruitment target (accounting for expected loss 
to follow- up). If sample size is not established based on the PRO endpoint, 
then discuss the power of the principal PRO analyses.
17–19
18a SPIRIT- 18a (i)- PRO Extension Justify the PRO instrument to be used and describe domains, number 
of items, recall period and instrument scaling and scoring (eg, range and 
direction of scores indicating a good or poor outcome). Evidence of PRO 
instrument measurement properties, interpretation guidelines and patient 
acceptability and burden should be provided or cited if available, ideally 
in the population of interest. State whether the measure will be used in 
accordance with any user manual and specify and justify deviations if 
planned.
19–20
SPIRIT- 18a (ii)- PRO Extension Include a data collection plan outlining the permitted mode(s) of 
administration (eg, paper, telephone, electronic, other) and setting (eg, clinic, 
home, other).
20–21
SPIRIT- 18a (iii)- PRO Extension Specify whether more than one language version will be used and 
state whether translated versions have been developed using currently 
recommended methods.
21–22
SPIRIT- 18a (iv)- PRO Extension When the trial context requires someone other than a trial participant to 
answer on his or her behalf (a proxy- reported outcome), state and justify the 
use of a proxy respondent. Provide or cite evidence of the validity of proxy 
assessment if available.
22–23
18b SPIRIT- 18b (i)- PRO Extension Specify PRO data collection and management strategies for minimising 
avoidable missing data.
23–24
SPIRIT- 18b (ii)- PRO Elaboration Describe the process of PRO assessment for participants who discontinue 
or deviate from the assigned intervention protocol.
24–25
20a SPIRIT- 20a- PRO Elaboration State PRO analysis methods, including any plans for addressing multiplicity/
type I (α) error.
25–26
20c SPIRIT- 20c- PRO Elaboration State how missing data will be described and outline the methods for 
handling missing items or entire assessments (eg, approach to imputation 
and sensitivity analyses).
26–27
22 SPIRIT-22- PRO Extension State whether or not PRO data will be monitored during the study to inform 
the clinical care of individual trial participants and, if so, how this will be 
managed in a standardised way. Describe how this process will be explained 





      
Table 1. SPIRIT 2013 and SPIRIT- PRO Extension checklist: recommended items to address in a clinical trial protocol 3–8
Glossary of terms 10–11
Protocol template Online supplemental 
file 2
PRO, patient- reported outcome; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials.
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‘The specific measurement goal (ie, the thing that is to be 
measured by a PRO instrument). In clinical trials, a PRO 
instrument can be used to measure the effect of a medical 
intervention on one or more concepts. PRO concepts 
represent aspects of how patients function or feel related 
to a health condition or its treatment’.16
Domain
‘A subconcept represented by a score of an instrument 
that measures a larger concept comprised multiple 
domains. For example, psychological function is a larger 
concept with multiple domains (emotional and cognitive 
function) that are measured by relevant items.’16
Endpoint*
The variable to be analysed. It is a precisely defined vari-
able intended to reflect an outcome of interest that is 
statistically analysed to address a particular research ques-
tion. A precise definition of an endpoint typically spec-
ifies the type of assessments made, the timing of those 
assessments, the assessment tools used and possibly other 
details, as applicable, such as how multiple assessments 
within an individual are to be combined17 (eg, change 
from baseline at 6 weeks in mean fatigue score).18
Health-related quality of life
‘A multidimensional concept that usually includes self- 
report of the way in which physical, emotional, social or 
other domains of well- being are affected by a disease or 
its treatment.’19
Important or key secondary PROs/endpoints
Some PRO measures (particularly health- related quality- 
of- life measures) are multidimensional, producing several 
domain- specific outcome scales; for example, pain, 
fatigue, physical function, psychological distress. For any 
particular trial, it is likely that a particular PRO or PRO 
domain(s) will be more relevant than others, reflecting 
the expected effect(s) of the trial intervention(s) in the 
target patient population. These relevant PRO(s) and/
or domain(s) may additionally constitute the important 
or key secondary PROs (identified a priori and speci-
fied as such in the trial protocol and statistical analysis 
plan) and will be the focus of hypothesis testing. In a 
regulatory environment, these outcomes may support a 
labelling claim. Because these outcomes are linked with 
hypotheses (Consolidated Standards of Reporting Trials 
(CONSORT)- PRO Extension 2b),19 they may be subject 
to p value adjustment (or ‘α spending’). Beyond effi-
cacy/effectiveness, PROs may also be used to capture 
and provide evidence of safety and tolerability (eg, using 
the Patient- Reported Outcomes version of the Common 
Terminology Criteria for Adverse Events).20
Instrument
‘A means to capture data (eg, a questionnaire) plus all 
the information and documentation that supports its 
use. Generally, that includes clearly defined methods and 
instructions for administration or responding, a standard 
format for data collection and well- documented methods 
for scoring, analysis and interpretation of results in the 
target patient population.’16
Intervention/Treatment
A process or action that is the focus of a clinical study. 
Interventions include drugs, medical devices, procedures, 
vaccines and other products that are either investiga-
tional or already available. Interventions can also include 
non- invasive approaches, such as education or modifying 
diet and exercise.21
Item
‘An individual question, statement or task (and its stan-
dardised response options) that is evaluated by the patient 
to address a particular concept.’16
Observer-reported outcome
‘A measurement based on a report of observable signs, 
events or behaviours related to a patient’s health condi-
tion by someone other than the patient of a healthcare 
professional.’22
Outcome*
The variable to be measured. It is the measurable char-
acteristic that is influenced or affected by an individuals’ 
baseline state or an intervention as in a clinical trial or 
other exposure17 (eg, a fatigue score).
Patient-reported outcome
A PRO is any report of the status of a patient’s health 
condition that comes directly from the patient, without 
interpretation of the patient’s response by a clinician 
or anyone else and may include patient assessments of 
health status, quality of life or symptoms.16 19 PROs are 
assessed by self- reported questionnaires, referred to as 
PRO measures or instruments.17
Primary outcome
The most important outcome in a trial, prespecified in the 
protocol, providing the most clinically relevant evidence 
directly related to the primary objective of the trial.
Proxy-reported outcome
‘A measurement based on a report by someone other 
than the patient reporting as if he or she is the patient.’16
Secondary outcomes
Outcomes prespecified in the protocol to assess addi-
tional effects of the intervention; some PROs may be 
identified as important or key secondary outcomes.
SPIRIT Elaboration item
An elaboration of an existing SPIRIT item as applied to 
a specific context; in this instance, as applied to clinical 
trials assessing PROs.
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SPIRIT-PRO Extension item
An additional checklist item describing PRO protocol 
content to address an aspect of PRO assessment that is 
not adequately covered by SPIRIT, as judged by available 
evidence and expert opinion.
Time-window
A predefined time frame before and after the protocol- 
specified PRO assessment timepoint, whereby the result 
would still be deemed to be clinically relevant.23
*The terms outcome and endpoint are often used 
interchangeably, although this is not always consistent 
with the range of definitions available. For the defini-
tions included in this glossary, an endpoint is defined 
from PRO data (ie, the outcome) by fully specifying four 
components: measurement variable (eg, fatigue ‘in the 
past week’ as measured by the QLQ- C30), analysis metric 
(eg, change in fatigue from baseline, final fatigue value, 
time to clinically important increase in fatigue (and 
‘event’), method of aggregation (eg, median fatigue, 
proportion of patients with severe fatigue, proportion 
of patients with clinically important change in fatigue) 
and timepoint. Note that using these definitions, several 
endpoints can be defined from the same outcome source 
data, revealing the distinction and relationship between 
‘outcome’ and ‘endpoint’ for PROs.
PURPOSE AND DEVELOPMENT OF THE EXPLANATION AND 
ELABORATION PAPER AND PRO PROTOCOL TEMPLATE
The SPIRIT- PRO Extension, this E&E and the included 
PRO protocol template are intended to guide the devel-
opment of trial protocols for ethical review, where PROs 
are a primary or key secondary outcome, including 
single- arm and multi- arm trials. We recommend that 
authors also consider inclusion of checklist items when 
PROs are exploratory in nature, as appropriate. Protocols 
may be formatted in accordance with local requirements, 
however they need to address the SPIRIT- PRO items 
completely and transparently. The examples provided 
in this E&E document and protocol template are not 
intended to be prescriptive about how information is 
included in protocols, nor how trials be conducted. Trial-
ists may, for example, wish to include a PRO- specific, 
dedicated section in the protocol with content informed 
by the SPIRIT- PRO checklist, while others may wish to 
add PRO content to existing sections of the protocol.
Modelled after other reporting guidelines,2 24 25 this 
E&E paper presents each checklist item with at least one 
example from a trial protocol, followed by an explanation 
of the rationale and main issues to address, to facilitate 
understanding and usage. The guidelines are intended to 
be used in conjunction with the SPIRIT- PRO Extension, 
SPIRIT 2013 Statement and E&E paper and other rele-
vant extensions.1 2 10 26 Empirical data and references to 
support each SPIRIT- PRO item are provided. Real- world 
examples for each SPIRIT- PRO item, quoted verbatim, 
are presented to reflect how key elements could be 
appropriately described in a trial protocol. These exam-
ples were obtained from E&E paper authors, public 
websites, journals, trial investigators and industry spon-
sors. Some examples illustrate a specific component of a 
checklist item, while others encompass all key recommen-
dations for an item. Reference numbers cited in the orig-
inal quoted text are denoted by (Reference) to distinguish 
them from references cited in this E&E paper. Health- 
related quality of life (HRQL) has been used consistently 
to replace terms for quality of life in examples.
ADMINISTRATIVE INFORMATION
SPIRIT-5a-PRO Elaboration
Specify the individual(s) responsible for the PRO content 
of the trial protocol.
Example
Trial name: multicentre randomized controlled trial of 
conventional versus laparoscopic surgery for colorectal 
cancer within an enhanced recovery programme 
(EnROL)
PRO endpoints: 1°, 2°








SP, [address, telephone]; JB, [address, telephone], LD, 












HW, [address, telephone]; MG, [address, telephone].27
Explanation
For trials assessing PROs, input from a person with 
expertise in PRO methodology early in the development 
phase of the protocol will improve its completeness and 
quality.10 Providing names and contact details of those 
contributing to the PRO- specific aspects of the protocol 
provides recognition, accountability and transparency. It 
aids identification of competing interests and prevents 
ghost authorship. It also provides a named point of 
contact to resolve any PRO- specific queries from other 
research team members, protocol reviewers and sites 
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(during trial start- up and conduct). Acknowledgements 
of PRO protocol input from patient- partners as per guide-
lines for the reporting of patient and public involvement 
is also recommended.28 Patient and public involvement 
in all aspects of trial design, including but not limited to: 
selection of outcomes and measures, timepoints, mode of 
assessment and reporting, can help minimise burden and 
ensure that data collected is patient- centred and relevant 
to participants and to the future patients who will benefit 
from the research.
Only 7 of 75 (9%) protocols that included PROs from 
the UK National Institute for Health Research (NIHR) 
Health Technology Assessment programme explicitly 
described who was responsible for the PRO component 
(online supplemental 1).3
SPIRIT-6a-PRO Extension
Describe the PRO- specific research question and ratio-
nale for PRO assessment and summarise PRO findings in 
relevant studies.
Example
Trial name: a phase III, randomised, double- blind, 
placebo- controlled study evaluating the efficacy and safety 
of idelalisib (GS-1101) in combination with rituximab for 
previously treated chronic lymphocytic leukaemia (CLL)
PRO endpoints: 2°
Endpoint selection rationale
Health-related quality of life
‘Direct patient reporting of outcomes using standardised 
methods has become an increasingly important compo-
nent of therapeutic assessment. Evaluation of PROs is 
particularly relevant in patients who cannot be cured of 
disease (Reference).
PRO questionnaires have been previously used in CLL 
to understand how patients differ from the general popu-
lation in terms of health concerns (References), to under-
stand differences in perceptions of well- being in younger 
versus older patients (References), to determine how treat-
ment affects HRQL (References), and to assess the pharma-
coeconomic cost of improvements in HRQL (Reference).
Patients with CLL have overtly impaired well- being 
relative to comparable controls (References). Fatigue 
is cited as a common complaint, being present in the 
substantial majority of patients. Impairment of HRQL 
prior to any treatment is apparent in those with B symp-
toms or in patients with anaemia, supporting the concept 
of initiating treatment when patients experience symp-
tomatic disease. Factors associated with lower overall 
HRQL have included older age, greater fatigue, severity 
of comorbid health conditions, advanced stage and 
ongoing treatment for CLL (Reference). Younger patients 
appear to have worse emotional and social well- being 
but older patients experience worse physical HRQL 
(Reference). In comparative evaluation of chemotherapy- 
containing regimens, differences in HRQL between ther-
apies (eg, fludarabine vs fludarabine- cyclophosphamide 
vs chlorambucil) reflected differences in toxicity while 
greater efficacy was associated with improved HRQL 
(References).
In this phase III study of GS-1101 and rituximab, it is 
postulated that incremental GS-1101- mediated tumor 
control will be correlated with greater positive changes 
in HRQL and that assessments of the drug’s safety profile 
will be supported by HRQL evaluations.’29
Explanation
A summary of available PRO evidence and a clearly 
defined PRO question is required in the background 
section of the protocol, or a dedicated PRO section if 
appropriate. Researchers should demonstrate the need 
for the research and identify the PRO- specific research 
question to demonstrate the scientific approach and 
integrity of the PRO study. This should include a review 
of existing PRO evidence from relevant trials and obser-
vational studies (eg, same/similar target population or 
intervention). This will avoid duplication of research, 
establish the burden of disease from the patient perspec-
tive, identify likely effects of treatment and inform 
objectives, hypotheses, selection of measures, endpoint 
definition and analyses (covered by subsequent SPIR-
IT- PRO items).
Many protocols include PROs without specifying the 
PRO- specific research question and without a rationale 
or any reference to PROs in related studies.3 4 9
Provision of this information can inform and moti-
vate research personnel to take note of PRO assessment 
methods and adhere to standardisation of PRO assess-
ment (eg, when, where, how and who of PRO assessment, 
as outlined in the protocol under subsequent SPIRIT- PRO 
items).6 11 Staff who understand the importance of PROs 
in a trial are able to share this understanding with partic-
ipants. The combined effect of motivated and co- opera-
tive staff and participants may help reduce missing PRO 
data rates.30 This information is also relevant to research 
ethics committees/institutional review boards (IRBs) and 
funders responsible for reviewing the scientific integrity 
and ethical aspects of the trial.
SPIRIT-7-PRO Extension
State- specific PRO objectives or hypotheses (including 
relevant PRO concepts/domains).
Examples
Trial group name: Trans Tasman Radiation Oncology 
Group (TROG)
Trial name: a randomised phase III trial of high- dose 
palliative radiotherapy (HDPRT) versus concurrent 
chemotherapy+HDPRT (C- HDPRT) in patients with 
good performance status, locally advanced or metastatic 
non- small cell lung cancer (NSCLC) with symptoms 
predominantly due to intrathoracic disease who are not 
suitable for radical chemo- radiotherapy (TROG 11.03 
P- LUNG GP)
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PRO endpoints: 1°, 2°
Objectives
‘The primary objective is to compare, in this group of 
patients, HDPRT versus C- HDPRT, with respect to
 ► the relief of dyspnoea, cough, haemoptysis and chest 
pain as assessed by change in total symptom burden 
from baseline to 6 weeks after the completion of 
treatment;
 ► response for each component symptom separately 
(dyspnoea, cough, haemoptysis, chest pain).
The secondary objectives are to compare the two regi-
mens in terms of dysphagia during treatment, thoracic 
symptom response rate, duration of thoracic symptom 
response, HRQL, toxicity, progression- free survival (PFS) 
and overall survival.
The exploratory/tertiary objectives are
 ► to determine how much improvement in HRQL and 
symptom palliation would be necessary to make the 
inconvenience due to the longer duration of radio-
therapy of C- HDPRT worthwhile, relative to HDPRT. 
This objective will be addressed in the patient prefer-
ences substudy;
 ► to analyse serum protein glycosylation changes and 
exosomes to identify potential biomarkers of disease 
response and progression. Prospectively collect and 
bank tumour tissue and blood samples from this 
cohort of patients for future evaluation of potential 
biological markers.’31
Trial name: evaluating different rate control therapies in 
permanent atrial fibrillation: a prospective, randomised, 
open- label, blinded endpoint trial comparing digoxin 
and beta- blockers as initial RAte control Therapy Evalua-
tion in permanent Atrial Fibrillation (RATE- AF)
PRO endpoints: 1°, 2°, exploratory
Hypothesis
‘Null hypothesis for primary outcome: no difference 
in patient- reported quality of life (measured using the 
physical functioning domain of the 36- Item Short Form 
Survey (SF-36) questionnaire) when comparing a strategy 
of digoxin versus beta- blocker therapy for initial rate 
control in patients with permanent AF.
Alternative hypothesis: use of digoxin or beta- blocker 
therapy as initial rate control in patients with permanent 
AF is superior based on patient- reported quality of life 
(measured using the physical functioning domain of the 
SF-36 questionnaire).
Primary objective
 ► Patient- reported quality of life (HRQL), with a prede-
fined focus on physical well- being using the SF-36 
physical component summary at 6 months.
Secondary objectives
 ► Generic and AF- specific patient- reported HRQL using 
the SF-36 global and domain- specific scores, the Atrial 
Fibrillation Effect on QualiTy of Life (AFEQT) overall 
score and the 5- level EQ- 5D version (EQ- 5D- 5L) 
summary index and visual analogue scale at 6 and 12 
months.
 ► Echocardiographic left ventricular ejection fraction 
and diastolic function (E/e’ and composite of dias-
tolic indices) at 12 months.
 ► Functional assessment, including 6- min walking 
distance achieved, change in European Heart Rhythm 
Association class and cognitive function at 6 and 12 
months.
 ► Change in B- type natriuretic peptide levels as a surro-
gate for total cardiac strain at 6 months.
 ► Change in heart rate from baseline and group compar-
ison using 24- hour ambulatory ECG.’32
Explanation
The PRO objectives should reflect the research ques-
tion to be addressed in the trial (SPIRIT- 6a- PRO Exten-
sion) and be described in the context of the population, 
intervention, comparator, outcome and timepoint and 
the estimand framework.33 Study objectives may focus 
on measuring treatment benefit (superiority), non- 
inferiority, equivalence. Alternatively, or in addition to 
one of these objectives, the trial may focus on assessing 
the safety and tolerability from the patient perspective, 
or may be more exploratory in nature, where results are 
presented but no comparative conclusions can be drawn. 
The PRO- specific study objectives need to clearly align 
with the proposed analyses methods (SPIRIT- 20a- PRO 
Elaboration). Critically, as described in work by the Setting 
International Standards in Analysing Patient- Reported 
Outcomes and Quality of Life Endpoints (SISAQOL) 
Consortium,34 four key attributes need to be considered a 
priori for each PRO domain:
1. Broad PRO research objective/research question.
2. Between- group PRO objective.
3. Within- treatment group PRO assumption for the treat-
ment or control arm.
4. Within- patient/within- treatment PRO objective 
(please note this component of the objective directly 
addresses the SPIRIT-12- PRO Extension).
More detailed information on how these can be applied 
are described in the SISAQOL consensus recommenda-
tions.34 Although the SISAQOL recommendations were 
published for oncology trials, the principles apply more 
broadly. Prespecification of objectives and hypotheses 
encourages identification of key PRO domains and time-
points. This is particularly important because PRO data 
are multidimensional in two important ways. First, there 
is often more than one relevant PRO in a trial, particularly 
when the high- level outcome of interest is HRQL. Many 
HRQL questionnaires yield separate scores for distinct 
dimensions, such as physical, emotional and social func-
tioning, as well as key symptoms such as fatigue and 
pain. Second, PRO assessments are typically scheduled at 
several timepoints during a trial, such as baseline, end of 
treatment, then a series of long- term follow- ups. Prespec-
ification of objectives and hypotheses—focussing on the 
most important PRO domains and timepoints—is a good 
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way to reduce multiple statistical testing and avoid selec-
tive reporting of PROs based on statistically significant 
results. Exploratory, hypothesis generating, analyses can 
also be undertaken but should be specified as such in the 
final trial report.19 This links to the SPIRIT- 20a- PRO Elab-
oration, which includes plans for addressing multiplicity/
type 1 (α) error. The objectives are generally phrased 
using neutral wording (eg, ‘to compare the effect of treat-
ment A vs treatment B on fatigue’) rather than in terms 
of a particular direction of effect.2 35 In contrast, the PRO 
hypothesis states the predicted effect of the interventions 
on the trial outcomes (eg, ‘patients allocated to treatment 
A will have less fatigue than those allocated to treatment 
B’).36–38
Despite the importance of clearly defined PRO objec-
tives and hypotheses, a review of trial protocols deter-
mined that 23% failed to include PRO- specific objectives 
and 81% were missing a clear PRO hypothesis.3
METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOMES
SPIRIT-10-PRO Extension
Specify any PRO- specific eligibility criteria (eg, language/
reading requirements or prerandomisation comple-
tion of PRO).30 If PROs will not be collected from the 
entire study sample, provide a rationale and describe the 
method for obtaining the PRO subsample.
Example
Trial group name: South West Oncology Group (SWOG)
Trial name: health status and quality of life in patients 
with early stage Hodgkin’s disease: a companion study to 
SWOG-9133 (SWOG S9208)
PRO endpoints: 1°, 2°
‘Eligibility criteria
Ages eligible for study: 18 years and older (adult, older 
adult)
Sexes eligible for study: All
Accepts healthy volunteers: No
Sampling method: Non- probability sample
Study population: community sample.
Criteria: disease characteristics: patients must be 
eligible for and registered to SWOG-9133.
Patient characteristics: patients must be able to 
complete the questionnaires in English. If they are not 
able to complete questionnaires in English, patients may 
be registered to SWOG-9133 without participating in 
SWOG-9208.’
The Symptom and Personal Information Question-
naire #1, the Cancer Rehabilitation Evaluation System 
Short Form and Cover Sheet must be completed prior to 
registration and randomisation on SWOG-9133.39
Explanation
Any eligibility criteria relevant to PRO assessment should 
be considered during the trial design and clearly spec-
ified in the protocol for consistent use by research 
personnel. In some trials, the baseline PRO assessment 
is required before randomisation as an eligibility crite-
rion.30 This helps to ensure there will be a valid baseline 
questionnaire from all patients, which is essential for 
calculation of change scores, or inclusion as a covariate in 
modelling longitudinal PRO data. For unblinded trials, 
this also ensures PRO data are collected before partici-
pants are aware of the randomisation which may affect 
some aspects of the participant’s response, for example, 
anxiety/emotional well- being.40 In the absence of such an 
eligibility criterion, there is a risk that the baseline assess-
ment may be conducted after randomisation but before 
the intervention is administered, resulting in detection 
bias. The maximum time between this assessment and 
randomisation should be defined and should not be too 
long.
It may not always be possible to collect PROs from all 
study participants, for example, due to non- availability 
of questionnaires in appropriate languages (see SPIRIT- 
18a(iii)- PRO Extension),9 literacy requirements or due 
to cognitive function (see SPIRIT- 18a(iv)- PRO Exten-
sion). These PRO- relevant exclusions typically should not 
preclude the affected participants from enrolling in the 
trial, unless the PRO is the primary outcome. Evidence 
suggests eligibility criteria as stated in trial protocols often 
differ from what is finally reported in the trial publica-
tion,41 and data on use of other language or culturally 
appropriate PRO instruments is often missing from the 
protocol.13 42
Where the needs of specific groups have been iden-
tified (eg, not fluent in English) but not accommo-
dated in the study protocol (eg, non- English language 
versions not available, assistance with reading and 
writing English version not permitted), this should 
be stated, and the rationale for the sampling method 
described and justified. Trialists should aim to be as 
inclusive as possible. Given the significance of PROs, 
the research community has a moral obligation to, 
where possible, to address gaps in availability of cultur-
ally validated PRO instruments. In the meantime, the 
implications for generalisability of findings should be 
discussed in subsequent publications.19
SPIRIT-12-PRO Extension
Specify the PRO concepts/domains used to evaluate 
the intervention (eg, overall HRQL, specific domain, 
specific symptom) and, for each one, the analysis 
metric (eg, change from baseline, final value, time 
to event) and the principal timepoint or period of 
interest.
Examples
Trial name: evaluating different rate control ther-
apies in permanent atrial fibrillation: a prospec-
tive, randomised, open- label, blinded endpoint trial 
comparing digoxin and beta- blockers as (RATE- AF)
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PRO endpoints: 1°, 2°, exploratory
Primary outcome
‘Patient- reported quality of life (HRQL)—SF-36 physical 
component summary score at 6 months.
Secondary outcomes
Patient-reported HRQL
 ► SF-36 global and domain- specific scores at 6 and 12 
months.
 ► EQ- 5D- 5L summary index and visual analogue scale at 
6 and 12 months.
 ► AFEQT overall score at 6 and 12 months.’32
Trial name: a phase III, randomised, double- blind, 
placebo- controlled study evaluating the efficacy and 
safety of idelalisib (GS-1101) in combination with ritux-
imab for previously treated CLL
PRO endpoints: 2°
‘Change in HRQL domain and symptom scores based on 
the Functional Assessment of Cancer Therapy: Leukaemia 
(FACT- Leu)—defined as the change from baseline and 
the time to definitive increments or decrements of 10%, 
20% and 40% from baseline; time to definitive increment 
(better than baseline by the specified amount) is the 
interval from randomisation to the first timepoint when 
the HRQL measure is consistently better than at baseline 
(including that timepoint as well as all the subsequent 
timepoints) in a subject whose last HRQL score is better 
than at baseline; and time to definitive HRQL decre-
ment (worse than baseline by the specified amount) is 
the interval from randomisation to the earliest of death 
or the first timepoint when the HRQL measure is consis-
tently worse than at baseline (including that timepoint as 
well as all the subsequent timepoints) in a subject whose 
last performance status score is worse than at baseline.’29
Explanation
For each outcome, including PROs, the trial protocol 
should define four components: the specific measure-
ment variable, which corresponds to the data collected 
directly from trial participants (eg, Beck Depression 
Inventory score, all- cause mortality); the participant- level 
analysis metric, which corresponds to the format of the 
outcome data that will be used from each trial participant 
for analysis (eg, change from baseline, final value, time 
to event); the method of aggregation, which refers to the 
summary measure format for each study group (eg, mean, 
proportion with score >2) and the specific measurement 
timepoint of interest for analysis.1 Many PRO question-
naires are multidimensional, assessing multiple facets 
of the impact of a disease and its treatment and usually 
include multiple assessments over the course of the trial. 
The multidimensional nature of PROs is most apparent 
in HRQL questionnaires, which often include various 
aspects of functioning and symptoms, which are often 
scored as distinct ‘domains’. These domains may not be 
affected equally by the trial interventions. The SPIRIT-
7- PRO Extension encourages protocol writers to identify 
the domains that are most likely to be affected in the trial 
objectives and hypotheses, drawing on previous evidence 
(SPIRIT- 6a- PRO Extension). The SPIRIT-12- PRO Exten-
sion item reinforces the statement of these key domains, 
and also the most important timepoints (ie, where 
greatest impact of interventions are expected), and 
develops that concept further by encouraging protocol 
contributors to think about how these PRO domains and 
timepoints will be analysed, that is, the analysis metric.34 
To ensure transparency and credibility of the analysis, it is 
recommended that there is prespecification of the PRO 
concepts/domains, analysis metric(s) and timepoint(s) 
of interest, whether the PRO is a primary, secondary or 
exploratory outcome. These should closely align with the 
study hypotheses/objectives and the nature and trajec-
tory of the disease or condition under investigation.34 43 
The selected key domains, timepoints and analysis metric 
should be used to specify the PRO endpoints, integrated 
in the full endpoint model of the trial.
A clearly defined endpoint model, organising all trial 
outcomes (PRO and non- PRO), typically in primary, 
secondary and exploratory endpoints, allows rigorous 
control of the evidence demonstration, especially the 
control of the statistical testing. Each PRO endpoint in 
the model should explicitly specify a single domain and a 
single time horizon. The endpoint model enables proce-
dures for type I error control (risk of false positive finding) 
(see SPIRIT- 20a- PRO Elaboration). Broadly, the concepts 
and domains (sub concepts) measured by a PRO may be 
‘proximal’ in nature, that is, direct impact of the disease 
and treatment (eg, symptoms such as pain, fatigue, 
nausea, rash and anxiety) or more distal, ‘knock- on’ 
effects, (eg, functional status and global quality of life), 
as illustrated for ovarian cancer in (figure 1, inspired by 
the Wilson and Cleary model44). Of note, the Food and 
Drug Administration (FDA) are increasingly focused on 
the individual measurement of well- defined concepts that 
impact on HRQL but are more proximal to a therapy’s 
effect on the patient and the patient’s disease: symptom-
atic adverse events, physical function and, where appro-
priate, a measure of the key symptoms of the disease.45
Figure 1 Proximal and distal effects of therapy on patient 
symptoms and quality of life. Adapted from Wilson and 
Cleary.44
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Common analysis metrics may include magnitude of 
event at time t, proportion of responders at time t, overall 
PRO score over time or response patterns/profiles. These 
should be prespecified alongside the levels of statistical 
and clinical significance for the study and any responder 
definition in use.16 Timepoints for analysis should be 
chosen to best address the research question, while 
taking into account aspects such as the natural history 
of the disease/condition and its treatment, the PRO 
measurement properties and recall period and partici-
pant completion burden.16 46
The example, idelalisib and rituximab improve PFS 
over rituximab alone in unfit patients with relapsed 
CLL: a phase III study, illustrates a ‘time to event’ PRO 
endpoint or analysis metric, where the event is defini-
tive improvement or definitive deterioration in a PRO. 
This approach allows repeated PRO measurements to be 
converted to a single measure: time to definitive incre-
ment or decrement. This requires quite complex and 
specific criteria for degree and duration of change. Also, 
this particular example does not specify any key domains 
of the FACT- Leu, but rather applies this analysis metric 
to all HRQL domain and symptom scores. In contrast, 
the RATE- AF example identifies a single score (the SF-36 
physical component score), and a specific timepoint 
(6 months) as the primary outcome, with other SF-36 
domains, questionnaires and timepoints specified as 
secondary outcomes.
SPIRIT-13-PRO Extension
Includes a schedule of PRO assessments, providing a ratio-
nale for the timepoints and justifying if the initial assess-
ment is not prerandomisation. Specify time- windows, 
whether PRO collection is prior to clinical assessments, 
and, if using multiple questionnaires, whether order of 
administration will be standardised.
Examples
Trial group: TROG
Trial name: a randomised phase III trial of HDPRT 
versus concurrent C- HDPRT in patients with good perfor-
mance status, locally advanced or metastatic NSCLC with 
symptoms predominantly due to intrathoracic disease 
who are not suitable for radical chemo- radiotherapy 
(TROG 11.03 P- LUNG GP) (figure 2).31
Trial group: UK Medical Research Council Scottish 
Cancer Trials Breast Group in association with: Breast 
International Group
Trial name: MRC phase III randomised trial to assess 
the role of adjuvant chest wall irradiation in ‘interme-
diate risk’ operable breast cancer following mastectomy 
(MRC SUPREMO TRIAL (BIG 2–04) (figures 3 and 4))
Explanation
A clear and concise schedule of PRO assessments 
(figures 2–4) can: assist trial staff to be organised and 
prepared for participant visits, inform study participants 
about the methods and expectations of trial participation 
and facilitate review of participant burden by research 
ethics committees/IRBs.30 The scheduled PRO assess-
ments should provide the data required to address the 
study’s PRO objectives. When selecting appropriate time-
points for assessment, it is important to consider the 
natural history of disease/progression, the hypothesised 
impact of therapy over time and practical considerations 
such as alignment of assessments with clinic visits and 
recall period of PRO measures. PRO assessments should 
be described in the protocol text and in the schedule of 
assessment table along with the other clinical data collec-
tion activities, for ease of reference. This is recommended 
whether the PRO is completed by the participant during 
study visits or outside of the study visits (eg, at home).
The timing of the baseline PRO assessment relative 
to other study- related events is important and there-
fore should be specified in the schedule of assessments. 
Collecting PRO data prior to randomisation helps ensure 
an unbiased baseline assessment, and if specified as an 
eligibility criterion, can promote data completeness 
(SPIRIT-10- PRO Extension). Baseline PRO data are often 
used as a covariate in analyses and are essential to calcu-
lating change from baseline, however, collecting data 
from enrolled patients prior to randomisation can be 
logistically challenging. One approach is to have partic-
ipants complete the baseline PRO assessment immedi-
ately after providing consent, while the site staff obtain 
the randomisation assignment from the study system. 
However, there may be scenarios in which prerandomis-
ation PRO assessment is unnecessary or not possible, for 
example, emergency surgery trials.
Stating the time- windows for each PRO assessment 
clearly in the protocol text and schedule of assessments 
table or footnote will help staff adhere to them. Examples 
of time- windows for PRO assessment are similar to time- 
windows for other types of assessments, such as a study 
visit that may occur on day 10–14 postbaseline, or on day 
30±3 days postsurgery. Time- windows for each scheduled 
Figure 2 Example schedule of patient- reported outcome 
(PRO) assessments in the Trans Tasman Radiation Oncology 
Group 11.03 P- Lung GP Trial. QoL, quality of life.
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PRO assessment require an unambiguous reference 
point, to ensure that PRO data collection captures clin-
ically relevant timepoints of interest. In deciding the size 
of the time- window for a PRO assessment, consider the 
trade- off between a smaller, more precise, time- window 
and a larger more feasible window. One approach is to 
specify a time- window that is a little larger than the ideal 
and not allow exceptions; this approach is more consis-
tent than setting a smaller time- window and allowing 
exceptions. Often PRO assessments that occur during 
active treatment, for example, chemotherapy, have a 
smaller time- window to capture acute toxicity that arise 
and resolve relatively quickly, while those occurring many 
months or years after treatment completion can have a 
larger window if the participant’s outcomes are expected 
to stabilise over time.
When the PRO assessment occurs during a research 
or clinic visit, it is recommended that PRO assessment is 
standardised to be completed prior to clinical consulta-
tion, assessments or procedures. For example, if a PRO 
instrument assesses participants’ experiences of pain in 
the past 7 days, and the study visit includes a bone marrow 
biopsy, the schedule of assessments should indicate that 
the PRO assessment be completed prior to the biopsy. 
This will prevent the pain assessment from capturing pain 
associated with the biopsy, reduce risk of missing data as 
participants may not feel well enough to complete PROs 
following their procedure and offer a ‘routine’ for study 
staff responsible for data collection.
When more than one PRO questionnaire is scheduled, 
it is recommended that the order of questionnaires is 
standardised, with those higher in the endpoint hierarchy 
being collected first.
These two forms of standardisation of PRO adminis-
tration are examples of the more general principle in 
research methodology that standardisation of methods 
reduces unwanted sources of variation, whether random 
(ie, no net effect on estimates of interest, such as the 
impact of interventions on PROs) or systematic (ie, 
causing bias).
SPIRIT-14-PRO Elaboration
When a PRO is the primary endpoint, state the required 
sample size (and how it was determined) and recruitment 
target (accounting for expected loss to follow- up). If 
sample size is not established based on the PRO endpoint, 
then discuss the power of the principal PRO analyses.
Examples
Trial name: the chronic autoimmune thyroiditis quality of 
life selenium trial (CATALYST)
PRO endpoints: 1°
‘The primary outcome is thyroid- related quality of 
life during 12 months’ intervention, as measured by a 
composite score from the ThyPRO questionnaire. Sample 
size estimation is based on this outcome.
The trial should be sufficiently powered to identify a 
difference between the intervention and the control 
group of 4 points on the 0–100 ThyPRO composite scale, 
corresponding to a small to moderate effect. In previously 
obtained data, the SD of ThyPRO- scores (sigma level) was 
20 points. With a correlation between observations on the 
Figure 3 Example schedule of patient- reported outcome assessments in the MRC SUPREMO TRIAL (BIG 2–04).140 BNP, B- 
type natriuretic peptide; QoL, quality of life.
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same participant of 0.50, and a power of 80% and a type 
I error probability (two- sided α level) of 0.05, a sample 
size of 236 experimental participants and 236 control 
participants is required. The sample size estimate is based 
on a design with five repeated measurements having a 
compound symmetry covariance structure’.47
Trial name: cosmesis and body image after single- 
port laparoscopic or conventional laparoscopic chole-
cystectomy: a multicentre double- blinded randomised 
controlled trial (SPOCC- trial)
PRO endpoints: 1°, 2°
‘The primary endpoint of the study concerns patient’s 
satisfaction with cosmesis and body image 12 weeks 
after surgery. This endpoint is assessed using a validated 
cosmesis and body image score (CBIS) that was previously 
used in surgery for Crohn’s disease and in donor nephrec-
tomy. This score is calculated on an 8- item multiple choice 
type questionnaire ranging between 8 and 48 points.
A clinically relevant improvement of the CBIS is 
defined as an improvement of 20% of the cosmesis score 
(8 points). Given the reported SD of the CBIS between 
4 and 6 and using (alpha=0.05 and beta=0.90), two 
groups of 49 patients are needed. This is based on a two- 
sided significance level (alpha) of 0.05 and a power of 
0.90. Estimating a 10% dropout rate, which is common 
in randomised controlled trials, 55 patients will be 
randomised per arm.’48
Trial group: TROG
Trial name: a randomised phase III study of radiation 
doses and fractionation schedules for ductal carcinoma 
in situ of the breast (BIG 3-07/TROG 07.01)
PRO endpoints: 2°
The sample size for this trial, based on the primary 
endpoint (time to local recurrence of invasive or intra-
ductal breast cancer in the ipsilateral breast), was 1600 
patients. The sample size for the PRO substudy was deter-
mined a priori, and was less than that required for the 
primary endpoint, as explained in the protocol excerpt 
below. Therefore, patients recruited after the PRO- 
specific target sample size was achieved did not complete 
PRO questionnaires, saving trial resources in data collec-
tion and management.
‘Sample size determination: for the quality of life study 
aiming to detect a difference between the tumour bed 
boost and no boost groups of 0.2 SD of a continuous scale 
such as fatigue or physical symptoms, with 80% power at 
a two- sided alpha level of 5%, the required sample size is 
790 patients. To allow for attrition at a rate of 5% per year, 
1020 patients are required to participate in the quality of 
life study.’49
Explanation
As with any primary endpoint, including those that focus 
on PRO, the criteria and methods for estimating the 
necessary sample size should be specified, with adjust-
ments for expected discontinuation from the clinical 
study.46 Ideally, the criteria for clinical significance (eg, 
minimal important difference, clinically meaningful 
within- patient change threshold, responder definition) 
should be specified when known.50 51 It is important to 
note that the FDA is more interested in what constitutes 
a meaningful within- patient change in score from the 
patient perspective.16
In cases where the PRO is specified as a key secondary 
endpoint, the statistical power based on the estimated 
sample size for the primary endpoint, should be deter-
mined. If overpowered, specifying a smaller PRO- specific 
sample size will save trial resources, as illustrated in the 
BIG 3–07/TROG 07.01 example. When sufficient power 
may be achieved by collecting PROs from a representa-
tive subset of participants, the sampling strategy should 
be clearly described.
Only 50.7% of NIHR Health Technology Assessment 
clinical trial protocols address sample size and statistical 
power for PRO specified as secondary endpoints.3 If the 
clinical trial is international in scope, the sampling across 
countries may be influenced by availability of language 
Figure 4 Flow diagram schedule of patient- reported 
outcome assessments in the MRC SUPREMO TRIAL (BIG 
2–04).140 BNP, B- type natriuretic peptide; QoL, quality of life.
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translations.52 In addition, the variability of measure-
ment between countries may inflate type 2 error (reduces 
power).
METHODS: DATA COLLECTION, MANAGEMENT AND ANALYSIS
SPIRIT-18a(i)-PRO Extension
Justify the PRO instrument to be used and describe 
domains, number of items, recall period, instrument 
scaling and scoring (eg, range and direction of scores 
indicating a good or poor outcome). Evidence of PRO 
instrument measurement properties, interpretation 
guidelines and patient acceptability and burden should 
be provided or cited if available, ideally in the popula-
tion of interest. State whether the measure will be used in 
accordance with any user manual and specify and justify 
deviations if planned.
Examples
Trial name: impact of a multimodal support intervention 
after a ‘mild’ stroke (YOU CALL- WE CALL)
PRO endpoints: 1°, 2°
‘A number of quality of life tools were reviewed (eg, 
SF-36, Stroke Impact Scale, Quality of Life Index (QLI)) 
and the tool chosen was a compromise between psycho-
metric properties and adequacy of content for mild 
stroke. The 32- item questionnaire QLI (Reference) which 
was developed from Ferran’s conceptual model of quality 
of life and which has been used with a stroke clientele 
(Reference) was chosen as the primary outcome. Each item 
of the QLI as relating to four life domains (health and 
functioning, socioeconomic, psychological/spiritual and 
family), is evaluated in terms of satisfaction and impor-
tance on a 6- point scale. Scores for each domain and a 
global score are expressed from 0 to 30, with a higher 
score indicating a better quality of life. These four life 
domains relate well with the main issues covered through 
the WE CALL intervention. It has shown to have adequate 
psychometric properties (concurrent validity, test–retest 
reliability and high internal consistency: a=0.90) (Refer-
ence) and thus should be responsive to therapy- induced 
change (Reference). A 1- point difference was observed in 
the first 6 months poststroke descriptive follow- up (n=63) 
for an effect size of 0.33 (Reference). A 2- point difference 
is considered a clinically meaningful change leading to a 
moderate effect size of 0.66.’53
Trial name: a randomised phase II/III multicentre clin-
ical trial of definitive chemoradiation, with or without 
cetuximab, in carcinoma of the oesophagus (SCOPE 1: 
Study of Chemoradiotherapy in Oesophageal Cancer 
Plus or Minus Erbitux)
PRO endpoints: 2°
HRQL instruments
‘Generic domains of HRQL will be assessed with the 
EORTC core Quality of Life Questionnaire, the EORTC 
QLQ- C30 (Reference). This instrument has been well 
validated in many international clinical trials in oncology 
including oesophageal adenocarcinoma and squamous 
cell cancer. Disease- specific and Chemoradiotherapy 
(CRT)- associated symptoms and side effects will be 
assessed with the oesophageal cancer- specific module, 
the EORTC QLQ- OES18 (Reference). This has been vali-
dated and tested in patients receiving definitive CRT. 
The module includes scales assessing dysphagia, eating 
restrictions, reflux, dry mouth and problems with saliva 
and deglutition. The Dermatology Life Quality Index 
(DLQI) will also be administered (Reference). This is a well- 
validated, easy- to- use index which assesses the impact of 
dermatological conditions on patients’ HRQL (Reference). 
It has been included to accurately assess the impact of the 
acneiform eruption commonly seen with cetuximab.’54
Explanation
The justification for the selection of PRO instrument(s) 
is required in the trial protocol. This will help trial 
personnel and participants understand why specific 
measures are being used and how they directly address 
the trial objectives and stakeholder needs.11 For example, 
regulatory agencies often focus on physical symptoms 
and functioning to inform licensing and labelling claims, 
whereas patients and health- policy makers may be more 
interested in broader aspects of HRQL, such as engaging 
in social activities and emotional well- being.55 56 For 
regulatory trials, it is prudent to seek regulatory advice 
at an early stage of trial development regarding the 
acceptability of the instrument and the approach to PRO 
assessment. Stakeholder- relevant PROs can be identified 
through patient involvement, qualitative research or core 
outcome sets,56 57 which alongside clinical outcomes, 
often include outcomes such as symptom burden, func-
tioning, and disease control, which can be measured 
using PRO instruments.
Appropriately developed and evaluated PRO instru-
ments can provide more sensitive and specific measure-
ments of the effects of medical intervention, thereby 
increasing the efficiency of clinical trials that attempt to 
measure the meaningful treatment benefits of those ther-
apies.58–60 Irrespective of whether the trial is conducted 
for regulatory purposes, FDA guidance and ISOQOL 
guidance provide a useful conceptual framework to assist 
in the selection of measures.16 61 Identifying and selecting 
valid, reliable tools that are acceptable to patients from the 
target population may prove challenging. The Consensus 
Based Standards for the Selection of Health Measurement 
Instruments (COMET) initiative and the Evaluating the 
Measurement of Patient Reported Outcomes programme 
provide useful guidance to support the review of measure-
ment properties.56 62 63
Ideally, the PRO instrument(s) will have been validated 
in the target population and this evidence cited. This will 
help reviewers understand if claims being supported by 
the PRO instrument can be substantiated by the evidence 
for using that instrument in that, or a related, population. 
Further details on the domains, number of items, recall 
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period, instrument scaling and scoring (eg, range and 
direction of scores indicating a good or poor outcome) 
should be provided. This will assist trial personnel in 
the collection and analysis of the PRO data. Question-
naires should be used in accordance with user manuals 
to promote good data quality and ensure standardised 
scoring. Deviations from user manuals or different ways 
of capturing PRO data may invalidate the measure; there-
fore, any deviations should be declared and transparently 
reported.19
If in the trial there are plans to use a questionnaire 
which has not been validated in the trial’s target popula-
tion, or if a new instrument is being developed alongside 
the trial, it is important to explain this in the protocol. 
Including an outline of any plans for the evaluation of its 
measurement properties using the trial data, if this will be 
undertaken, and if not why. This should be in accordance 
with established current guidelines for PRO validation.64
Although all the reviewed NIHR Health Technology 
Assessment clinical trial protocols identified the PRO 
instrument to be used in the trial, few justified their use 
in relation to the study hypotheses, PRO instrument 
measurement properties or expected participant burden 
(41.3%, 37.3% and 14.7%, respectively).3
Patient partners involved in the design of the study can 
assist with the selection of PRO instruments and provide 
feedback on the likely acceptability of the questions, 
and participant burden (eg, time taken for completion, 
cognitive burden, emotional burden, repetition across 
questionnaires).65 The number of PRO instruments/
questions to be assessed in a trial requires careful justifica-
tion. Minimising participant burden has been identified 
as a strategy to reduce risk of missing PRO data, improve 
recruitment and retention.30
SPIRIT-18a(ii)-PRO Extension
Includes a data collection plan outlining the permitted 
mode(s) of administration (eg, paper, telephone, elec-
tronic, other) and setting (eg, clinic, home, other).
Examples
Trial name: early surgery versus optimal current 
step- up practice for chronic pancreatitis: a multicentre 
randomised controlled trial
PRO endpoints: 1°, 2°
‘The Izbicki pain score will be assessed every 2 weeks 
during a follow- up period of 18 months. For this end, 
the Izbicki pain score will be assessed via a web question-
naire. Patients who do not have an email will be given a 
folder with Izbiki pain score forms and return envelops. 
Patients will be contacted by telephone every 2 weeks and 
reminded to fill in the questionnaire and send it to the 
trial coordinators. The Izbicki pain score is a one page 
questionnaire, easily completed in <3 min. The folder 
with the Izbicki score forms will be re- filled at every outpa-
tient clinic visit (scheduled every 6 months).’66
Trial name: a randomised multistage phase II/III study 
of sunitinib comparing temporary cessation with allowing 
continuation, at the time of maximal radiological 
response, in the first- line treatment of locally advanced/
metastatic renal cancer (STAR)
PRO endpoints: 1°, 2°
Quality of life questionnaires during the first 6 months 
will be administered in clinic in order to support partici-
pant use before postal questionnaires are instituted after 
6 months for the EQ- 5DTM/EQ- VAS (Functional Assess-
ment of Cancer Therapy - General (FACT- G) and Func-
tional Assessment of Cancer Therapy- Kidney Symptom 
Index (FSKI) will continued to be collected at clinic visits). 
Clinic staff should remind participants of the importance 
of the quality of life assessments at each clinic visit.
Due to the importance of HRQL data in this trial, 
measures will be taken to ensure maximum compliance 
of questionnaire completion. For the 2 weekly question-
naires which participants complete at home from the 
24- week timepoint, where the participant consents to 
this, reminders for completion are sent by email or text 
message to the participant by the research team at the 
Clinical Trials Research Unit (CTRU): this is an optional 
part of the STAR Informed Consent Form. Where a 
HRQL questionnaire would be completed at a hospital 
clinic visit, but the local research team forget to give this 
to the participant, of the participant no longer attends 
clinic visits at hospital during their follow- up period, a 
questionnaire for the local research team will send this 
out by post to the participant’s home after checking the 
participant’s status and establishing it is appropriate to 
do so.67 68
Explanation
Standardisation of all aspects of PRO administration 
is vital to PRO data quality. It is therefore critical that 
research personnel and trial participants understand 
how, when and where PRO data will be collected in the 
study.10 The study protocol should specify the permitted 
mode(s), method(s) and setting(s) of PRO data collec-
tion, including the permitted ‘back- up’ options and 
preplanned reminders. For example, when PRO assess-
ment is conducted in clinic via a tablet computer, paper 
forms could be permitted (and available) as a back- up 
option for instances when the tablet is not available or 
functioning properly. Offering alternative modes of 
completion may help improve response rates.30 Of note, 
the FDA has previously recommended that there is a 
back- up plan for electronic PRO data collection (eg, web- 
based, phone- based or paper- based) implemented in case 
of malfunctions with electronic devices.69
Electronic PRO assessment is increasingly available 
in trials, but traditional paper- based methods may still 
be useful or required in some situations. It is therefore 
important to know whether there are systematic differ-
ences induced by mode of administration. A recent 
meta- analysis that included 31 studies that randomised 
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participants to different data collection modes found 
no evidence of bias associated with paper versus elec-
tronic administration.70 These results support the use 
of multiple modes of administration within a research 
study, which may be a useful strategy for reducing missing 
PRO data. If evidence of equivalence between different 
modes of administration is available for the specific PRO 
questionnaires in a trial, it should be considered in deter-
mining the PRO administration plan. If electronic admin-
istration has not been attempted before for the trial PRO 
questionnaires, and only minor modifications to layout/
presentation are needed with respect to the paper- based 
versions, it is advisable to pilot- test usability and conduct 
cognitive debriefing to assess equivalence.70 71 The Inter-
national Society for Pharmacoeconomics and Outcomes 
Research provide useful guidance on key considerations 
for PRO data collection including multiple modes.71 72
The setting for PRO data collection, for example, in 
clinic or at home (or clinic at baseline, with follow- up at 
home), should be described and standardised across trial 
intervention groups and sites. Differential use of settings 
and modes of administration by treatment arm should be 
avoided as these may lead to different response rates and 
potentially biased results.11
The protocol should also specify the types of assistance 
trial staff can provide patients for completing the PRO 
assessment. Respondents should be encouraged to self- 
complete as far as possible. Some respondents may require 
some assistance, however, the greater the degree of assis-
tance, the greater the potential to influence a respon-
dent’s responses. Assistance should therefore be limited, 
provided only by a trained member of the research team, 
or a trained third party, the permissible types of assistance 
should be clearly specified in the protocol and reviewed 
in staff training. Allowable assistance might include 
instructions on how patients can input their answer on 
the tablet, clarifying the response options, reading ques-
tions to the participant or recording the participants’ 
answer on the form/tablet. This level of assistance facili-
tates self- administration of the PRO instrument. Comple-
tion of a PRO instrument with an interpreter, caregiver 
or family member should be avoided as these individuals 
have not been trained, and may influence the individ-
ual’s responses, either directly by expressing opinions 
that influence the participant to alter their answers, or 
indirectly, for example, if the respondent seeks to avoid 
embarrassment or to provide a more acceptable answer 
(social desirability bias).
Furthermore, use of a human language interpreter 
should be avoided. When planning a study, common 
languages spoken by patients attending the recruiting 
centres should be considered so that validated language 
translations of chosen PRO instruments can be obtained 
(see SPIRIT- 18a(iii)- PRO Extension).
Interviewer administration of PRO instruments should 
be avoided, but where necessary, should be clearly justi-
fied in the protocol. Interviewers should read questions 
verbatim, ideally using a PRO instrument that has been 
validated in that mode. Similarly, proxy or observer 
completion requires a proxy- validated/observer- reported 
version of the PRO instrument (see SPIRIT- 18a(iv)- PRO 
Extension).
SPIRIT-18a(iii)-PRO Extension
Specify whether more than one language version will 
be used and state whether translated versions have been 
developed using currently recommended methods.
Example
Trial name: A Phase III, randomised, open label trial of 
lenalidomide/dexamethasone with or without elotu-
zumab in relapsed or refractory multiple myeloma 
(ELOQUENT – 2)
PRO endpoints: 2°, exploratory
Outcomes research assessments
HRQL assessments
‘To assess the impact of treatment, subject’s quality of 
life will be measured using three validated HRQL instru-
ments: the European Organization for Research and 
Treatment of Cancer Quality of life Questionnaire- Core 
(EORTC QLQ- C30), the myeloma- specific module (QLQ- 
MY20) and the Brief Pain Inventory- Short Form (BPI- SF).
Non- English- speaking subjects will complete the ques-
tionnaire using validated language transitions developed 
and recommended for each instrument. The BPI- SF has 
demonstrated both reliability and validity across cultures 
and languages, and has been used to study the effective-
ness of pain treatment.(Reference) A score of 6 on a scale 
of 0–10 on any single item is generally considered to be 
clinically significant.(Reference) Pretesting was carried 
out in the UK, Norway, Sweden, Denmark and Germany. 
Field testing of the module has been conducted in a 
range of phase III trials.(Reference) The module has been 
validated in a large number of languages (see www. eortc. 
be/ home/ qol).’73
Explanation
Trials involving participants with different language 
requirements require measures that have been trans-
lated and culturally adapted using appropriate meth-
odology.10 12 74 75 Providing culture- appropriate and 
language- appropriate PRO instruments for use in the 
trial can lead to a reduction in missing data, ability to 
recruit people from ethnic minority groups, lower attri-
tion rates and improved generalisability of trial results.76 
If the countries/languages are not known at the time of 
protocol writing then more general protocol content may 
be appropriate:
multiple language validated versions are available 
[provide references where these can be found] and 
the correct language for this patient should be used.
At present, the extent to which this is happening is not 
clear. A review of protocols and/or subsequent publica-
tions from cancer clinical trials with a PRO endpoint, 
registered on the NIHR portfolio examined reporting of 
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ethnically diverse recruitment and the use of culturally 
and linguistically validated PRO instruments. The review 
found a lack of transparency around the use of cultur-
ally and linguistically appropriate PRO instruments. Of 
the 88 studies reviewed, only 14 (17%) reported any type 
of data on ethnic diversity. Although eight studies were 
multicentre, multinational cancer clinical trials, none 
identified if translated versions of PRO instruments were 
being used.77
There are clear guidelines for translating PRO instru-
ments,74 78 and plans to use translated versions, should 
be specified in the protocol, citing references when 
available.10 Specification of use of translated versions 
in the protocol will help reporting in accordance with 
CONSORT- PRO.19 74 75 It must not be assumed that 
linguistic translation equates to cross- cultural adaptation 
(preparing the instrument for use in another setting). 
A number of studies79 80 have recommended that cross- 
cultural equivalence is also an important consider-
ation.74 75 81
Using different language versions of PRO instru-
ments to collect data in a trial ideally requires evidence 
to support the psychometric equivalence of data being 
reported, especially if data are going to be pooled for clin-
ical trial evaluation.52 82 83 Where such evidence is unavail-
able, prespecification in the statistical analysis plan (SAP) 
of exploratory analyses to assess whether there are differ-
ences between PROs by language group may be appro-
priate. The language in which each patient complete 
the questionnaire should be recorded in the database to 
inform such analyses.52
SPIRIT-18a(iv)-PRO Extension
When the trial context requires someone other than a 
trial participant to answer on his or her behalf (a proxy- 
reported outcome), state and justify the use of a proxy 
respondent. Provide or cite evidence of the validity of 
proxy assessment if available.
Examples
Trial name: cognitive rehabilitation in paediatric 
acquired brain injury—a randomised controlled trial 
(CORE- pABI)
PRO endpoints: 1°, 2°
‘[Paediatric Acquired Brain Injury] constitutes a major 
disruption to child development and may affect cogni-
tive, behavioural, emotional, social as well as academic 
function.
The primary outcome measure is the BRIEF, parent 
report (Reference). BRIEF is an 86- item standardised ques-
tionnaire that captures parents perceptions of a child’s 
executive function in his or her everyday environment. 
Each item’s frequency of occurrence is rated on a 3- point 
Likert scale from 1 (never) to 3 (often). It has demon-
strated good reliability, with high test–retest reliability 
(r=0.88 for teachers,82 for parents), internal consistency 
(Cronbach’s α=0.80–0.98) and moderate correlations 
have been detected between teacher and parent ratings 
(r=0.32–0.34). The questionnaire has been applied to 
several clinical groups in Norway.’84
Trial name: evaluating the effectiveness and cost effec-
tiveness of dementia care mapping (DCM) to enable 
person- centred care for people with dementia and their 
carers: a cluster randomised controlled trial in care 
homes (DCM EPIC study 1.0)
PRO endpoints: 2°
‘Relative/friend criteria
To be eligible to provide proxy data about a resident, 
relatives/friends must: have visited the resident on a 
regular basis over the past month (ie, at least once per 
week). Be willing to provide data at a time convenient to 
them. Have sufficient proficiency in English to contribute 
to the data collection required for the research.’85
Explanation
In some contexts, such as trials involving young children 
or cognitively impaired participants or participants who 
are unable to reliably self- report for other reasons, it may 
be necessary for a proxy—someone other than a trial 
participant, to report the participant’s outcomes on their 
behalf as though they are the patient.10 86
Proxy reports should be used only when necessary. The 
European Medicines Agency states that ‘in general proxy 
reporting should be avoided, unless the use of such “proxy 
raters” may be the only effective means of obtaining infor-
mation that might otherwise be lost.’16 43 The US FDA 
also discourages the use of proxy- reported outcomes to 
inform labelling claims, recommending observer reports 
for observable phenomenon only (eg, vomiting, but not 
nausea) instead.
In contexts such as cancer, dementia or palliative care, 
it is reasonable to anticipate the need for proxy response 
throughout all or some of the trial. Previous studies have 
shown varying levels of agreement between participant 
and proxy ratings, dependent on the variable being 
measured, the quality, duration and stability of the rela-
tionship between proxy and participant.87 88
A trial protocol should indicate clearly who is eligible 
to provide the proxy report, with explicit administration 
guidelines for completion of proxy measures including 
how the report is to be captured, whether that same 
individual must be the ‘consistent rater’ across all time-
points of assessment (this is preferable, for consistency), 
or whether varying proxy reports will be permissible. 
This information should also be provided for observer- 
reported outcomes.
Just as the measurement properties of the PRO instru-
ment should be specified, so should the properties of 
measures to be used by proxy reporters.
Given known issues with patient and proxy reporter 
discordance,88–91 while patient- participants are still able 
to self- complete, collecting both participant and proxy- 
reported data enables quantification of the size and direc-
tion of any bias, that may later be adjusted for, if needed. 
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Further data may be gathered about the proxy (eg, age, 
relationship to the patient, gender, proxy literacy, rela-
tionship and exposure to the patient92) as these variables 
may guide interpretation of results and any subgroup/
sensitivity analyses. Whether proxy- reported data will be 
analysed separately or pooled with participant- reported 
data should also be detailed. Any such plans should be 
specified in the protocol and SAP. This information 
should also be provided for observer- reported outcomes.
SPIRIT-18b(i)-PRO Extension
Specify PRO data collection and management strategies 
for minimising avoidable missing data.
Examples
Trial group: National Cancer Institute, Naples
Trial name: phase III randomised multicentre trial of 
carboplatin+liposomal doxorubicin versus carboplat-
in+paclitaxel in patients with ovarian cancer (Multicentre 
Italian Trials in Ovarian Cancer-2 (MITO-2))
PRO endpoints: 2°
‘Operating procedure:
 ► It is fundamental that the researchers take great care 
when collecting the questionnaires, in order to allow 
good compliance by the patients participating in the 
protocol.
 ► The quality of life form must be filled in by the patient 
herself.
 ► The quality of life form must be filled in before the 
clinical examination, and thus before the discussion 
with the examining doctor which may provide favour-
able or unfavourable information about the disease’s 
status.
 ► When supplying the form to the patient, it is impor-
tant to explain how to fill it in without going into 
details about the contents of the questions.
 ► After the form has been returned, check that the 
patient has answered all the questions and ask her to 
reply to any questions she has skipped.
 ► The quality of life questionnaires must be filled in 
using a black or blue pen.’93
Trial group: National Cancer Institute of Canada Clin-
ical Trials Group (NCIC CTG)
Trial name: a double- blind randomisation to letrozole 
or placebo for women previously diagnosed with primary 
breast cancer completing 5 years of adjuvant aromatase 
inhibitor either as initial therapy or after tamoxifen 




‘Mandatory for NCIC CTG centres and optional for 
centers within other cooperative groups:
Patient is able (ie, sufficiently fluent) and willing 
to complete the two quality of life questionnaires in 
either English or French. The baseline assessment must 
have been completed prior to randomisation. Inability 
(illiteracy in English or French, loss of sight or other 
equivalent reason) to complete questionnaires will not 
make the patient ineligible for the study. However, ability 
but unwillingness to complete the questionnaires will 
make the patient ineligible.’94
Explanation
Missing PRO data are a particular problem because data 
cannot be obtained retrospectively or from medical 
records. Missing PRO data may arise from different 
sources95 and, broadly speaking, missing data can be 
attributed to causes that are unavoidable or avoidable. 
Unavoidable reasons may include if a participant has died 
or become too unwell to self- complete PRO instruments. 
Avoidable reasons may include some type of human error 
that could have been prevented. Examples of avoidable 
missing data include: staff failing to hand out a scheduled 
questionnaire; a participant not realising the question-
naire is double- sided so missing half of the questions; an 
electronic PRO device not being charged; the internet 
or server being down; when the PRO assessment is overly 
burdensome on the patient (eg, due to the burden of 
multiple questionnaires at one time or repetitive scales) 
so the patient decides not to complete it.
Although ‘unavoidable’ types of missing data are more 
challenging for interpretation because the missing data 
may be related to the measured outcome and it is impos-
sible to accurately calculate the extent of any associated 
bias,96 97 avoidable types of missing data are also problem-
atic.30 Avoidable missing PRO data compromise the inter-
pretability, accuracy and value of PRO findings because 
study power is reduced, which increases the risk of type 2 
errors,96 and because any assumptions made during the 
analysis about missing PRO values are not verifiable.98
There are a range of design, implementation and 
reporting strategies to help minimise and address missing 
PRO data,30 most of which can be addressed in the trial 
protocol. Specific recommendations related to data 
collection and management include: refraining from 
administering an excessive number of questionnaires to 
participants (researchers should refrain from collecting 
more data than they really need), using standardised and 
documented PRO administration procedures, engaging 
and educating participants in the trial by providing 
updates or incentives, maintaining participant records, 
employing active quality assurance measures (such as 
real- time compliance/completion monitoring, sending 
reminders for upcoming or missed assessments, checking 
completed questionnaires for missing items while the 
participant is still present at clinic), appointing a dedi-
cated staff member responsible for PRO assessment 
at each centre, training staff about the importance of 
PROs as well as procedures for assessment, offering an 
alternative mode of administration if the participant is 
not able to complete the questionnaire via the primary 
mode (eg, completing the questionnaire over the phone 
if the hardcopy cannot be completed at the clinic within 
the acceptable time- window) and recording reasons for 
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missed assessments using standardised forms.30 From a 
regulatory perspective, the FDA encourages maintaining 
consistency in assessment methods, however, this should 
be balanced with reduction of missing data. If different 
modes are used, they should be justified and presented in 
the study documentation.99 If different modes are used, 
‘FDA will review the comparability of data obtained when 
using multiple data collection methods or administration 
modes within a single clinical trial to determine whether 
the treatment effect varies by method or mode.’69 Addi-
tional strategies are described in the full review.30
The MITO-2 and MA.17R examples above illustrate 
some of these strategies. MA.17R comes from the Cana-
dian Cancer Trials Group (CCTG), a multicentre coop-
erative oncology group that conducts clinical trials in 
cancer therapy, supportive care and prevention. The 
CCTG requires completion of the PRO questionnaire(s) 
as a prerandomisation eligibility requirement (as per 
SPIRIT-10- PRO Extension). This flags the importance of 
PRO data to investigators and clinical research associates, 
indicating PROs are as important as other inclusion clin-
ical criteria. It also helps to maximise compliance.
Our prior work suggests that few trials actively specify 
such procedures in their protocols; 46.7% HTA proto-
cols3 and 38.5% of international ovarian cancer trials4 
included strategies to minimise avoidable missing data.
SPIRIT-18b(ii)-PRO Elaboration
Describe the process of PRO assessment for participants 
who discontinue or deviate from the assigned interven-
tion protocol.
Examples
Trial name: a multicentre, open- label, randomised, two- 
arm phase III trial on the effect on PFS of bevacizumab 
plus chemotherapy versus chemotherapy alone in patients 
with platinum- resistant, epithelial ovarian, fallopian tube 
or primary peritoneal cancer (AURELIA)
PRO endpoints: 2°
AURELIA was a multicentre, open- label, randomised, 
two- arm phase III trial of bevacizumab plus chemotherapy 
versus chemotherapy alone in patients with platinum- 
resistant, epithelial ovarian, fallopian tube or primary 
peritoneal cancer (Reference). The primary endpoint 
was PFS; quality of life was a secondary endpoint. The 
protocol stated that:
‘On clear evidence of disease progression (PD) 
or toxicity, study therapy should be discontinued 
permanently.’
The protocol also specified postprogression treatment 
options: women who had been on the chemotherapy 
alone arm would have the option of bevacizumab alone 
or standard of care, while those who had been on the 
chemotherapy plus bevacizumab arm would receive stan-
dard of care treatment. The protocol stated that:
‘In case the patient decides to prematurely discontinue 
study treatment (“refuses treatment”), she should be 
asked if she can still be contacted for further information’ 
and that ‘after PD, patients will be followed for survival 
only.’
However, it lacked an explicit statement about PRO 
assessment postprogression, which may explain some 
inconsistency among sites, with some sites collecting PRO 
data postprogression, and other not.
As stated in the AURELIA PRO paper (reference, p1310), 
‘only questionnaires completed until PD were included 
in the main analyses. Questionnaires completed after 
PD were excluded based on the medical assumption that 
these patients were unlikely to be benefiting from their 
study treatment, may have been receiving another treat-
ment and were therefore not relevant to the intended 
comparison of chemotherapy alone versus bevacizumab 
plus chemotherapy. However, post hoc sensitivity anal-
yses were performed to determine the impact of ques-
tionnaires completed after PD.’ The latter analyses were 
consistent with the main analyses, but could perhaps have 
been avoided, and patients saved unnecessary HRQL 
assessment burden, if the protocol has contained a clear 
statement that HRQL assessments should cease at disease 
progression.100
Trial group: Australasian Leukaemia & Lymphoma 
Group (ALLG)
Trial name: BLAM- A phase IIb study of blinatumom-
ab+cytarabine (AraC) and methotrexate in adult B- pre-
cursor acute lymphoblastic leukaemia (ALLG ALL8)
PRO endpoints: 2°
ALLG ALL8 is a BLAM- A phase IIb study of blinatumom-
ab+cytarabine (AraC) and methotrexate in adult B- pre-
cursor acute lymphoblastic leukaemia (B- ALL). It is a 
single- arm study which aims to demonstrate preliminary 
evidence of the benefit of frontline blinatumomab in 
combination with cytarabine and methotrexate in adult 
B- ALL, and to demonstrate the ability of this combina-
tion to attain deep (MRDnegative) remissions and hence 
to reduce the need for allogeneic stem cell transplanta-
tion. The ALLG ALL8 protocol specifies that the decision 
for allogeneic stem cell transplantation is left up to the 
investigator, and that patients who proceed to allogeneic 
stem cell transplant discontinue the assigned interven-
tion protocol. Being recommended for allogeneic stem 
cell transplant is therefore a withdrawal criteria. However, 
patients do not have to withdraw—it is optional, the 
patient’s choice. The trial team is in fact interested in the 
experience of patients who proceed to allogeneic stem 
cell transplant. So the protocol states:
Subjects who proceed to allogeneic stem cell trans-
plant who have not withdrawn consent to the study 
should have FACT- Leu (HRQL questionnaire) assess-
ments performed 6- monthly.
This provides the trial team with the opportunity to 
document the experience of patients who proceed to 
allogeneic stem cell transplant in terms of the range of 
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common symptoms and aspects of well- being assessed by 
FACT- Leu.101
Explanation
A clear plan for collection of PROs for trial participants 
who withdraw early from a study or who discontinue the 
intervention helps minimise bias,102 ensures that staff 
collect all required PRO data in a standardised and timely 
way, and may assist ethical appraisal of the study.10 102
Often, participants can provide valuable PRO data even 
after stopping the assigned intervention protocol, whether 
due to personal choice and/or clinical recommendation, 
as illustrated in the one- arm phase II trial ALLG ALL8 
trial. However, this does not hold in all contexts (as illus-
trated in the AURELIA trial), a randomised phase III 
trial, in which participants whose cancer had progressed 
on their assigned treatments, were then often switched to 
alternative treatment.
Providing a clear description of the process of PRO 
assessment for participants who discontinue or deviate 
from the assigned intervention protocol and how the 
data will be used, enables all staff to follow a standardised 
procedure to collect the required PRO data in timely way 
and to avoid collecting data that will not contribute to 
analysis.
Correspondingly, the SAP should be clear on how such 
data will be handled. In the case where postdiscontinua-
tion/deviation PRO data are useful, the SAP should state 
the study objective that these data will address and how 
they will be analysed.
Participants should also be aware of this process, so a 
simple and clear description of whether or not they will 
be asked to continue to complete PRO questionnaires 
after stopping or changing the treatment they were 
initially allocated to should be included in the participant 
information sheet (PIS).
SPIRIT-20a-PRO Elaboration
State PRO analysis methods, including any plans for 
addressing multiplicity/type I (α) error.
Example
Trial name: a phase III, randomised double- blind, 
placebo- controlled study of the efficacy and safety of two 
doses of tofacitinib (Cp-690,550) in subjects with active 
psoriatic arthritis and an inadequate response to at least 
one tumour necrosis factor inhibitor (OPAL BEYOND)
PRO endpoints: 1°, 2°, exploratory
Analysis of primary endpoint
‘There are two primary endpoints in A3921125 and two 
doses of tofacitinib each of which will be compared with 
placebo for each endpoint. In order to control for type 
I error, a stepwise testing procedure will be used. This 
implies that a given endpoint for a given dose can only 
achieve significance if the prior endpoint is significant. 
The order of the fixed sequence for testing against 
placebo is as follows: tofacitinib 10 mg ACR20 response 
rate at 3 months, tofacitinib 5 mg ACR20 response 
rate at 3 months, tofacitinib 10 mg Health Assessment 
Questionnaire- Disability Index (HAQ- DI) at 3 months, 
tofacitinib 5 mg HAQ- DI at 3 months. This gate- keeping 
or step- down approach strongly protects the type I error 
rate at the 0.05 (two- sided) level.
ACR20 response
For all comparative analyses, the normal approximation 
for the difference in binomial proportions will be used to 
test the superiority of each dose of tofacitinib to placebo 
and to generate CIs for the differences. The primary anal-
ysis will be ACR20 response rate at month 3. The ACR20 
response rate will also be analysed at other timepoints as 
a secondary analysis.
Missing values due to a subject dropping from the study 
for any reason (eg, lack of efficacy or adverse event) will 
be handled by setting the ACR20 value to non- responsive.
HAQ-DI
The HAQ- DI score will be expressed as a change from 
baseline. The primary timepoint will be at month 3. The 
analysis will be done using a repeated measure model that 
includes fixed effects of treatment, visit (week 2, months 
1, 2 and 3), treatment by visit interaction, geographic 
location and baseline value. The model will use and fit an 
unstructured variance- covariance matrix. Full details will 
be listed in the analysis plan.
Additional analyses of the HAQ- DI will include a 
responder analysis at month 3 where subjects with a 
change of 0.3 will be considered responders and subjects 
who dropped from the study will be considered non- 
responsive. Another responder analysis will be conducted 
using a change of 0.35 at the cutpoint for response (Refer-
ence). The normal approximation for the difference in 
binomial proportions will be used for these responder 
analyses.
Analysis of secondary and other endpoints
Key secondary efficacy variables are as follows: PASI75, 
enthesitis score, dactylitis severity score, physical func-
tion domain of SF-36 and FACIT- F at month 3. In order 
to strongly protect the study- wise type I error rate with 
respect to these key secondary endpoints and the primary 
endpoints, these endpoints will be tested only if all 
endpoints/doses for the primary endpoints are statisti-
cally significant. The order of testing is as listed above; 
for each endpoint, tofacitinib 10 mg will be tested versus 
placebo first, followed by tofacitinib 5 mg. Testing stops 
at the first instance in which statistical significance is not 
achieved.
Methods for analysing all other endpoints will be 
enumerated in the statistical analysis plan. Briefly, binary 
variables (eg, remission rates) will follow the analyses 
described above for binary variables (eg, ACR20) and 
continuous endpoints will follow the same type of anal-
yses described above for continuous endpoints (eg, HAQ- 
DI). Descriptive statistics may also be calculated and 
displayed’.103
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Explanation
Statistical analysis of multiple domains10 104 and time-
points implies multiple hypothesis testing, which inflates 
the probability of false- positive results (type I error).46 
This can be contained by prespecifying the key PRO 
domain(s) or overall score of interest and the principal 
timepoint(s) which cross- reference to SPIRIT-7- PRO 
Extension and SPIRIT-12- PRO Extension.
Any plans to address multiplicity, such as stepwise or 
sequential analyses, whereby multiple endpoints are 
tested in a defined sequence that contains the overall 
type I error to the desired level, or conventional non- 
hierarchical methods (eg, Bonferroni correction), should 
be specified a priori.16 There are many strategies and/or 
choices of methods that may be appropriate.105 Family- 
wise type I error should be considered for all of the appli-
cable endpoints of the trials together and not for the PRO 
endpoints separately. Some clinical trials include PROs 
as exploratory endpoints and no adjustment is made for 
multiplicity in subscale scores administered at multiple 
study visits. These analyses may only provide limited infor-
mation on the tolerability of the intervention.
Protocols should make some reference to key consid-
erations for the analysis of the trial PROs (including any 
plans for addressing multiple testing), but the detail is 
often more appropriately included in the SAP, usually 
developed after the protocol. If no adjustments for type 
I error are to be made, then this should be clearly stated. 
However, clinical trial protocols in which PROs are 
secondary outcomes rarely include any information about 
PRO statistical analyses, beyond any that are prespeci-
fied as primary or key secondary endpoints or when the 
sponsor is interested in achieving a product label claim. 
Our review of trial protocols found that fewer than 2% 
provided information on the statistical analysis plans to 
address multiplicity for the PRO endpoints.3
SPIRIT-20c-PRO Elaboration
State how missing data will be described and outline the 
methods for handling missing items or entire assessments 
(eg, approach to imputation and sensitivity analyses).
Example
Trial group: European Organisation for Research and 
Treatment of Cancer- Gynaecological Cancer Group, 
and Gynecologic Cancer Intergroup (EORTC- GCG and 
GCIG)
Trial name: a randomised, multicentre, phase III 
study of erlotinib versus observation in patients with no 
evidence of disease progression after first line, platinum- 
based chemotherapy for high- risk ovarian epithelial, 




‘Missing data may hamper assessment of HRQL in clin-
ical trials. This may occur because centres do not collect 
the questionnaires at the appropriate time (unit non- 
response), and also because patients may not reply to 
questions within the questionnaires (item non- response). 
The latter problem occurs <2% on average and should 
not be a problem. The former problem will be mini-
mised by ensuring that participating centres are properly 
informed and motivated towards HRQL assessment.
During the study, compliance with completing HRQL 
questionnaires will be investigated at each timepoint. The 
compliance of the HRQL assessments will also be reviewed 
twice a year and will be a part of the descriptive report 
by the Data Center for the Group’s plenary sessions and, 
if possible, be presented by the EORTC Quality of Life 
Group’s appointed liaison person.
The compliance rate between the two arms will be 
compared at each timepoint using a χ2 test. In order to 
adjust for the multiplicity of the tests, a Bonferroni adjust-
ment will be made by which each test will be performed at 
the 0.01 significance level. Should follow- up compliance 
levels drop below 60% at subsequent biannual compli-
ance reviews, then the Protocol Writing Committee would 
review this to either improve compliance or consider 
terminating the HRQL assessment in the trial.
Missing data
When performing HRQL analyses complications may 
arise due to large quantities of missing data. This issue has 
a bearing on whether a valid comparison of the treatment 
arms is being made.
In HRQL research there are two main types of missing 
data: (1) item non- response, (2) unit non- response (the 
whole questionnaire is missing for a patient). As item 
non- response occurs <2% on average in the QLQ- C30, 
it is not such a major problem and thus the methods 
described in the EORTC QLQ- C30 scoring manual for 
handling item non- response will be used. For missing 
questionnaires, it is necessary to identify both the extent 
of missing questionnaires and the main process of missing 
data. Three different types of missing data processes may 
exist: missing completely at random (MCAR), missing 
at random (MAR) and missing not at random (MNAR, 
informative dropout mechanism). These have distinct 
consequences for data analysis (Reference).
If the missing data process is considered to be non- 
ignorable (MNAR), then quality of life will be compared 
between groups using longitudinal data modelling tech-
niques (ie, Proc mixed in SAS with either selection models 
or pattern- mixture models) in combination with a logistic 
regression for the dropout process. If the missing data 
mechanism can be considered ignorable (MAR), then 
standard longitudinal data analysis will be used (proc 
mixed in SAS). If the data are MCAR, then complete case 
analysis can be used without biasing the results.’106
Explanation
Most clinical trials with PROs will have some missing PRO 
data,98 yet a review of protocols found that less than half 
outlined statistical methods to deal with missing PRO data.3
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There are two types of missing PRO data: (1) missing 
items, when the participant completes some but not all of 
the questions within a PRO instrument and (2) missing 
assessments, when the participant does not complete a 
scheduled assessment at all (ie, there are no PRO data 
available for analysis from the participant at that assess-
ment timepoint). The latter type is more serious, as it 
potentially affects the choice of analysis method and the 
interpretation and generalisability of the results. The trial 
protocol should explain how both types of missing data 
will be handled in the analysis.
1. Handling missing items: many PRO scoring manuals 
provide guidance for handling missing items. A com-
mon approach is to impute the mean score of the com-
pleted items, if less than one- half of items comprising 
the scale are missing.107 108 This approach is possible 
for multi- item scales but it is not possible to impute 
scores for single item scales. Always consult the scoring 
manual to determine how to handle missing items, and 
cite the manual in the protocol. Missing items of PRO 
instruments that are underpinned by modern psycho-
metrics techniques (Item Response Theory or Rasch 
Measurement Theory) are naturally handled without 
requiring imputation.34 109
2. Handling missed assessments: missing assessments 
present a major problem for PRO analyses; lead to 
a loss of power and wider CIs from a lack of preci-
sion,110 111 and potentially to biased results. The risk of 
bias depends on the underlying cause of why data are 
missing (called the ‘missing data mechanism’), and 
this in turn should influence the choice of statistical 
analysis methods.
In order to gain insights into the mechanism of 
missing PRO data, it is helpful to ascertain and record 
reasons for missed PRO assessments during trial 
conduct. The protocol needs to describe how these 
reasons will be collected in a standardised manner. Typi-
cally, a standard form is used (which can be included in 
the online supplemental appendix along with the PRO 
questionnaires). Also, the form can be used to collect 
additional data (referred to as ‘auxiliary data’) related 
to ‘missingness’ or the PRO,30 which should be speci-
fied in the protocol.
The trial protocol should also provide a summary of 
how missing data will be described and handled in the 
analysis,10 and state that comprehensive details about 
the planned analysis will be provided in a subsequent 
SAP.112 The SISAQOL Consortium have developed a 
taxonomy of research objectives that can be matched 
with appropriate statistical methods for PRO anal-
ysis, standardised statistical terminology relating to 
missing data and are determining appropriate ways to 
manage missing data, currently focused in an oncology 
setting. A simulation study was done to assess whether 
it was possible to have a threshold to define substantial 
missing data.113 Although no agreement was reached 
for a threshold, the simulation study showed that the 
effect of missing data rates on PRO findings depends 
on the type of missing data (ie, informative or non- 
informative missing data). It was recommended that 
collecting reasons for missing data is key in assessing 
the effect of missing data for PRO findings.34 Addition-
ally, SISAQOL is developing a set of macros to describe 
patterns of missing data, and to evaluate imputation 
methods for use in sensitivity analysis.34 36 38
METHODS: MONITORING
SPIRIT-22-PRO Extension
State whether or not PRO data will be monitored during 
the study to inform the clinical care of individual trial 
participants and, if so, how this will be managed in a stan-
dardised way. Describe how this process will be explained 
to participants, for example, in the PIS and consent form.
Example
Trial name: the use of an electronic patient- reported 
outcome measure in the management of patients with 
advanced chronic kidney disease (RePROM)
PRO endpoints: 2°
Protocol
‘If, when reviewing the completed EQ- 5D- 5L question-
naire, the research nurse becomes concerned for the 
well- being of the participant, they should discuss their 
concerns with the participant directly, working in part-
nership to determine the best course of action. With the 
participant’s permission, the research nurse may need to 
consult with the PI and/or treating clinician to address 
these concerns. In exceptional circumstances, the 
research nurse may consult with the PI and/or treating 
clinician without the permission of the participant if they 
are concerned for the participant’s safety’.
Patient information sheet
‘If the study research nurse becomes concerned for your 
well- being during a study review, they will discuss their 
concerns with you, to determine the best course of action. 
With your permission, the research nurse may need to 
consult with a senior member of the study and/or your 
treating clinician to address these concerns. In excep-
tional circumstances, the research nurse may need to do 
this without your prior permission if they are concerned 
for your safety’.
Consent form
‘I understand that if the study research nurse becomes 
concerned for my well- being during a study review, they 
will discuss their concerns with me to determine the best 
course of action. With my permission, the research nurse 
may need to consult with a senior member of the study 
and/or my treating clinician to address these concerns. 
In exceptional circumstances, the research nurse may 
need to do this without my prior permission if they are 
concerned for my safety.’114
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Explanation
To protect participant safety, PRO data may be monitored 
during a study for signs of psychological distress or phys-
ical symptoms that may require an immediate response: 
so- called ‘PRO Alerts’.115 Examples of PRO data that may 
raise concern include signs of psychological distress, poor 
physical well- being or high symptom burden presenting 
as extreme scores on questionnaires. Concerns can also 
arise when additional information is provided by the 
participant (eg, through free text report), or in discus-
sions between the participant and research staff.115 The 
nature of some studies may mean that participants are 
more at risk than in others. In studies where prior risk 
assessment deems the probability of PRO alerts being 
generated by participants to be minimal, PRO data may 
not be reviewed until the end of the trial for pragmatic 
reasons, however, concerning PRO data, may still arise 
during the course of the study.11 116 If monitoring is not 
planned this should be stated. If monitoring is planned, 
steps for how PRO alerts will be dealt with should be 
included in the trial protocol, to provide immediate reas-
surance to concerned trial staff about how to proceed and 
promote appropriate clinical management and transpar-
ency considering professional obligations to patient care. 
Any arising interventions should be recorded. Evidence 
suggests the absence of such information leads to incon-
sistent handling of concerning data including adminis-
tration of non- prespecified interventions to aid the trial 
participant which risks co- intervention bias that is, bias 
caused by ‘any intervention other than the experimental 
manoeuver that alters the frequency of a trial’s outcome 
of interest’.12 116 117 Identifying participants at risk and in 
need of urgent attention through PRO monitoring is an 
ethical issue as is acknowledging that information identi-
fied in the completion of a PRO too may be shared with 
the clinical team when the need arises. Information about 
how the trial staff will respond to concerns, or alternative 
support mechanisms where monitoring is not taking 
place, should be provided to participants (in participant 
information and consent documentation). This infor-
mation provided in the patient information sheet (PIS) 
will manage participant expectations and ensure trans-
parent and explicit communication about the intended 
use of PRO study data in fulfilment of contemporary 
data protection laws, for example, the European Union 
General Data Protection Regulation.118
There is no regulatory requirement from the US FDA 
that PRO data measuring symptomatic side effects be 
monitored and alerts for these items created. However, 
it is good practice to remind participants at each PRO 
assessment whether their data are or is not being moni-
tored in real time. In the case PRO data are not being 
monitored, participants should be reminded to speak to 
clinical staff if they are experiencing a specific problem, 
symptom or side effect.
Protocol template
The PRO protocol template (online supplemental file 
2) aims to support protocol writing for pharmaceutical 
Box regulatory/HTA perspective
Regulatory agencies, such as the Medicines and Healthcare products 
Regulatory Agency, European Medicines Agency and FDA are plac-
ing more focus on capturing the patient experience when developing 
drugs.16 43 55 133 However, poorly defined PRO objectives have hindered 
the utility of PROs in regulatory decisions. Accurate and well- defined 
PRO methods can provide the patients’ perspective on the impact of 
a treatment on disease- related symptoms and symptomatic adverse 
events. Efforts to improve PRO clinical trial standards are welcomed and 
the SPIRIT- PRO extension provides an additional resource for drug de-
velopers to consider in their development programmes. Alongside these 
guidelines and other regulatory guidance documents, the importance of 
seeking early scientific advice directly from the regulatory authorities 
and health technology assessment bodies such as NICE cannot be un-
derstated, where advice can be given on the acceptability of a particular 
approach. Therefore, raising PRO standards is key to the successful in-
tegration of PROs in drug development programmes, ensuring that the 
impact of medicines on a disease can be captured from the patient’s 
perspectives.
Box patient perspective
What is the question that doctors and nurses ask their patients more 
than any other? “How are you feeling?” That is why we need PROs in 
clinical research. They allow patients to answer that question in a sys-
tematic and measurable way, which will benefit others and from which 
we may well benefit ourselves at some point.
For patients, including PROs in health and social care research studies 
is vital in assessing whether or not our health and/or well- being are 
improving. Well- designed PRO instruments will help assess our general 
health and emotional mood, our ability to complete our daily tasks and 
our self- measured levels of pain and/or fatigue.
PROs are very different from the clinical measures used to assess the 
effectiveness of new drugs or other treatments, yet for us, it is the PROs 
that measure ‘tolerability’ and thus the real- life ‘effectiveness’ of the 
drug or intervention as a medicine or treatment.
The ultimate measure of the performance of any health service must be 
in whether or not it helps people recover from an acute illness, live well 
with a chronic condition and face the end of life with dignity—and peo-
ple’s own reports on their own condition are the only valid way to gauge 
success. So if a drug or treatment is to be trialled for use in healthcare 
delivery, it is essential that PROs are included in the success criteria.
It is equally essential therefore that participants on the study understand 
the importance of completing PRO assessments and to understand how 
and why the data are collected. This should not be too onerous for re-
searchers to explain to patients. Patients who choose to participate in 
clinical trials do so because they wish to benefit others and if possible, 
to benefit themselves. PROs are a means of doing both—provided that 
the reporting and recording are not too much of a burden. “We must do 
all that we can to make patient- reported outcome assessment feasible 
and credible. If we fail in our task we will have left out the heart of all 
healthcare research: the patient”.141
And when we do complete our PROs on your research study, please let 
us know what happens to the study, what you know now that you did 
not know before, and how that will be used to help people. Because that 
is why we participate in research; it is to help people like us.









pen: first published as 10.1136/bm




29Calvert M, et al. BMJ Open 2021;11:e045105. doi:10.1136/bmjopen-2020-045105
Open access
companies, funders, clinicians and international trials 
groups by providing PRO content that can be incorpo-
rated directly into the relevant sections of existing clin-
ical trial protocols or retained as a dedicated PRO section 
within the protocol.
Supplementary trial documents
Online supplemental 2 outlines additional items recom-
mended for inclusion in other trial documentation, such 
as the SAP, PIS and training and guidance documents 
for staff.10 119 This is not an exhaustive list and further 
PRO content may be warranted in training materials and 
patient facing documents dependant on the trial. We 
recommend input from PRO experts working in conjunc-
tion with the clinical team, trials unit or Contract Research 
Organisation and patient partners involved in the co- de-
sign of research with regulatory input as required to opti-
mise the protocol and supplementary resources.
DISCUSSION
This paper provides a detailed rationale, implementation 
instructions and real- world examples to assist investiga-
tors to develop the PRO- specific components of clinical 
trial protocols, in accordance with the 16 items of the 
SPIRIT- PRO Extension. This SPIRIT- PRO Extension E&E 
paper is recommended for use alongside the original 
SPIRIT 2013 and SPIRIT- PRO guidelines.1 2 10 The mission 
of the SPIRIT- PRO Group is to improve the design and 
standardisation of PRO components of clinical trials and 
thereby ensure high- quality PRO data to inform patient- 
centred care. To further facilitate uptake of the SPIR-
IT- PRO items, we have provided a PRO- specific protocol 
template covering all the SPIRIT- PRO items. This can be 
used in two ways: either incorporated item- by- item into 
relevant sections of existing clinical trial protocols or 
retained whole as a dedicated PRO section within a trial 
protocol. The use of a template should support investiga-
tors to address all required SPIRIT- PRO checklist items 
comprehensively and meaningfully, in conjunction with 
the real- world examples provided for each SPIRIT- PRO 
item in this manuscript.
The overall aim of the SPIRIT- PRO Extension and E&E 
is to improve the completeness, quality and transparency 
of PRO sections of clinical trial protocols, where PROs 
are a primary or key secondary outcome. We also recom-
mend use of the guidelines to support development of 
protocols where PROs data are exploratory in nature, 
including single- arm trials with PRO endpoints. Many of 
the SPIRIT- PRO items may also provide useful prompts 
about PRO content for cohort studies and other non- 
randomised designs. The SPIRIT- PRO guidelines,10 and 
E&E paper aim to facilitate development of high- quality 
PRO protocol content, which will ultimately also facilitate 
the review of protocols by research ethics committees/
IRBs, scientific review groups and funders. Improved 
PRO protocol content has been associated with more 
complete reporting which will help facilitate the critical 
appraisal of final trial reports and results3 and use of PRO 
data to inform patient- centred care. Several SPIRIT- PRO 
items correspond to items on the CONSORT- PRO check-
list.10 19 This is particularly important since reviews of 
PRO reporting indicate that, where published PRO trial 
data were available, there was often considerable delay 
between publication of primary outcomes and the PRO 
results and standards of reporting were poor.4 5 7 9 120–123 
Worryingly, a recent review of cancer trials suggested that 
49 568 participants were involved in studies that failed 
to publish their PRO data and that poor reporting was 
associated with suboptimal PRO protocol content.9 This 
finding is consistent with findings from Schandelmaier et 
al, which demonstrated that 52% of cancer trials specified 
HRQL outcomes in their protocols, however, only 20% 
reported any HRQL data in associated publications.120 
Non- reporting of PRO findings is widespread,7 9 120–128 
meaning patient- centred information may not be avail-
able to benefit patients, clinicians and regulators. Non- 
reporting of these important patient data is unethical and 
is a waste of limited healthcare research resources.129–131 
In the EU Clinical Trials Regulation (536/2014), there 
will be a requirement for results of all primary endpoint 
and patient relevant secondary endpoints to be reported 
within 12 months of the end of the study.132 The provi-
sion of a protocol template alongside example excerpts 
from trial protocols will help facilitate protocol devel-
opers understand how to write high- quality PRO protocol 
content and support more complete reporting of results.
In a companion paper,15 we also present tools for 
patient advocates involved in the co- design of trial proto-
cols or the review of protocols through roles on ethics 
committees or funding committees with PRO endpoints 
to further optimise study design and facilitate patient 
involvement. It is essential that patients’ experiences, 
perspectives, needs and priorities are captured and mean-
ingfully incorporated. The SPIRIT- PRO Group and regu-
latory agencies strongly support the early and continued 
involvement of patients and members of the public in 
trial design and conduct.133 134
The next steps for the SPIRIT- PRO Initiative are to 
promote uptake and use of the guidelines and implemen-
tation tools and development of ethical guidelines for 
IRBs and ethics committees. The SPIRIT website ( www. 
spirit- statement. org) and PROlearn, a free resource on 
the optimal use of PROs in research and routine prac-
tice ( www. bham. ac. uk/ prolearn) provides the latest 
resources and information on the initiative, including a 
list of supporters. We invite international stakeholders to 
assist in the evaluation of the SPIRIT Statement and E&E 
paper by using the documents and providing feedback to 
inform future revisions.
SPIRIT- PRO forms part of a growing toolbox to promote 
the optimal use of PROs in trials including guidance 
for the selection of measures,61 design (SPIRIT- PRO),10 
analysis (SISAQOL),34 reporting (CONSORT- PRO)13 
and presentation of results (figure 5).135–137 These tools 
are currently being disseminated by the PROTEUS 
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Consortium (Patient- Reported Outcomes Tools: 
Engaging Users & Stakeholders) who aim to partner with 
key patient, clinician, research and regulatory groups 
around the world to promote the uptake and use of these 
methodological tools to optimise the assessment and 
reporting of PROs in clinical trials (https:// more. bham. 
ac. uk/ proteus/). Patient and public involvement in all of 
these activities can help ensure that PRO selection, study 
implementation and application is transparent, relevant 
and acceptable. Consistent with this philosophy, patient 
partners have been involved in all aspects of the develop-
ment of the SPIRIT- PRO Extension.10 138 139
Through widespread uptake and support, the potential 
to improve the completeness and quality of trial protocols 
and the efficiency of their review can be fully realised. 
Ultimately, high- quality PRO results can help ensure that 
important patient- centred evidence on the efficacy, safety 
and tolerability of interventions is available to inform 
shared decision- making, labelling claims, clinical guide-
lines and health policy.
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